

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


B5

(51) International Patent Classification ⁶ : C07K 14/00		A2	(11) International Publication Number: WO 98/46637
			(43) International Publication Date: 22 October 1998 (22.10.98)
(21) International Application Number: PCT/US98/07573 (22) International Filing Date: 16 April 1998 (16.04.98) (30) Priority Data: 08/843,659 16 April 1997 (16.04.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/843,659 (CON) Filed on 16 April 1997 (16.04.97) (71) Applicant (for all designated States except US): ARCH DEVELOPMENT CORPORATION [US/US]; 1011 East 58th Street, Chicago, IL 60637 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LEOPARDI, Rosario [IT/US]; 5107 S. Blackstone (906), Chicago, IL 60615 (US). ROIZMAN, Bernard [US/US]; 5555 S. Everett Avenue, Chicago, IL 60637 (US). (74) Agent: HIGHLANDER, Steven, L.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	

(54) Title: HERPES SIMPLEX VIRUS U_S3 AND ICP4 AS INHIBITORS OF APOPTOSIS

(57) Abstract

The ICP4 protein of herpes simplex virus plays an important role in the transactivation of viral genes. The present invention discloses that ICP4 also has the ability to inhibit apoptosis. This function appears to reside in functional domain distinct from the transactivating function, as indicated by studies using temperature sensitive mutants of ICP4 that have transactivating function at elevated temperatures. Also disclosed are methods for inhibition of apoptosis using ICP4 or an ICP4 encoding gene, such as an $\alpha 4$ gene, methods for inhibiting ICP4's apoptosis-inhibiting function, and methods for the production of recombinant proteins and treatment of HSV infections. Further, the present invention discloses that the HSV-1 mutant lacking the $\alpha 4$ gene, has a secondary mutation in the gene U_S3 specifying a protein kinase. Thus a functional U_S3, a viral gene encoding a protein kinase known to phosphorylate serine/threonine within a specific arginine rich consensus sequence, is required in order to block apoptosis. Also disclosed are methods for inhibition of apoptosis using U_S3 or an U_S3 encoding gene, methods for inhibiting U_S3's apoptosis-inhibiting function, and methods for the production of recombinant proteins and treatment of HSV infections.



BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTION**HERPES SIMPLEX VIRUS U_s3 AND ICP4 AS INHIBITORS OF APOPTOSIS****BACKGROUND OF THE INVENTION**

The government may own certain rights in this application by virtue of federal funding under grant numbers AI124009 (NIAID) and CA47451 (NCI).

I. Field of the Invention

5 The present invention relates to the fields of molecular and cell biology generally, and more specifically, it addresses mechanisms for growth control in eukaryotic cells. In particular, there are provided viral genes that inhibit normal cell death and methods for use thereof.

10 II. Related Art

The control of host cell gene expression, and often the control of genes involved in DNA replication, are integral parts of the life cycle of a virus. However, recent evidence suggests that most eukaryotic cells respond to viral disruption of normal cellular physiology by undergoing programmed cell death (apoptosis) (White, 1993). To counteract this, many viruses
15 have evolved mechanisms to block host cell death (Clem and Miller, 1994; White and Gooding, 1994). In several cases, viral genomes have been found to contain genes whose products interact with proteins that play a central role in regulating cell survival.

Programmed cell death is triggered by several factors and may take various forms. For example, the synthesis of double-stranded RNA activates kinases which phosphorylate the α
20 subunit of eIF-2 and completely turn off protein synthesis (Sarre, 1989). Ultimately, activation of metabolic pathways causes a pattern of morphological, biochemical, and molecular changes which result in cell death without spillage of cellular constituents which would result in an inflammatory response detrimental to the host (Wyllie, *et al.*).

Apoptotic cell death is commonly observed during embryogenesis and organ involution
25 and in the natural death of terminally differentiated cells at the end of their life span. Most viruses which induce either the shut-off of protein synthesis or apoptosis also have evolved mechanisms which block host responses and enable them to replicate in their hosts (Shen and Shenk, 1995).

Among the best-known examples of viral gene products which block apoptosis are the adenovirus E1B M_r19,000 protein (Rao, *et al.*, 1992.), vaccinia CrmA protein (Ray, *et al.*), simian virus 40 (SV40) T antigen (McCarthy, *et al.*, 1994), human papillomavirus No. 16 (HPV 16) E6 protein (Pan and Griep, 1994), Epstein-Barr virus BHRF1 protein (Henderson, *et al.*, 1993) and human
5 cytomegalovirus IE1 and IE2 gene products (Zhu, *et al.*, 1995). Herpes simplex virus 1 (HSV-1) encodes a protein, $\gamma_134.5$, which blocks the phosphorylation of eIF-2 α (Chou and Roizman, 1992).

The utility of proteins that are capable of inhibiting apoptosis are manifold. First, such proteins, or their corresponding genes, may be used to immortalize cell lines that otherwise
10 would perish during culture. This makes possible not only the study of these cells, but also presents the option of growing these cells in large numbers in order to isolate protein species therefrom. Second, the identification of inhibitors of apoptosis and their function permits the possible intervention, in a clinical setting, when these proteins are interfering with normal programmed cell death, or apoptosis. This may be accomplished by providing an inhibitor or
15 an antisense nucleic acid that interferes with the expression of a protein that interferes with apoptosis. Thus, the identification of novel proteins having these activities and uses provide important new tools for those working in this arena.

SUMMARY OF THE INVENTION

20 It is, therefore, an object of the present invention to provide methods for the use of U_S3 and its cognate gene U_S3 as inhibitors of apoptosis. The present invention further provides infected cell protein number 4, or ICP4, and its cognate gene α 4, as inhibitors of apoptosis. In addition, it is an object of the present invention to provide methods for the use of agents that inhibit US3 protein function and gene expression to induce apoptosis in HSV infected cells.
25 The present invention also provides methods for the use of agents that inhibit the apoptosis-induction function of US3 thereby to inhibiting apoptosis in virally infected cells. It is a further objective to provide methods of use of agents that inhibit ICP4 and/or α 4 in order to induce apoptosis in HSV infected cells. It also is an object of the present invention to provide methods for the identification of agents that inhibit the apoptosis-inhibiting function of ICP4.

In satisfying these goals, there is provided a method for blocking apoptosis of a cell comprising the step of providing to the cell an HSV U_S3 polypeptide or an HSV U_S3 gene. The U_S3 gene may be contained in an expression vector and, further, under the control of a promoter active in eukaryotic cells. One such promoter is the a tetracycline controlled promoter. The expression vector further comprises a selectable marker and/or further comprises a gene encoding a second polypeptide under the transcriptional control of a promoter active in eukaryotic cells.

The method may further comprise the step of providing to the cell an HSV ICP4 polypeptide or an HSV α 4 gene. The α 4 gene may be contained in an expression vector and, further, under the control of a promoter active in eukaryotic cells.

In another embodiment, there is provided a method for inducing apoptosis in a cell infected with HSV comprising the step of administering to said cell an agent that inhibits HSV U_S3 function in said cell. The agent may inhibit transcription or translation of an HSV U_S3 gene or transcript or may bind to an HSV U_S3 polypeptide. The reagent may be an antisense HSV U_S3 construct an antibody that binds immunologically to an HSV U_S3 polypeptide. Particular antisense constructs are oligonucleotides that hybridizes to a 5'-untranslated region for an HSV U_S3 gene or a translational start site for an HSV U_S3 transcript. Particular antibodies are polyclonal sera against U_S3 or a monoclonal antibody against U_S3.

In another embodiment, the method further comprising the step of administering to said cell an agent that inhibits HSV ICP4 function in said cell.. The agent may inhibit transcription or translation of an HSV α 4 gene or transcript or may bind to an HSV ICP4 polypeptide. The reagent may be an antisense HSV α 4 construct an antibody that binds immunologically to an HSV ICP4 polypeptide. Particular antisense constructs are oligonucleotides that hybridizes to a 5'-untranslated region for an HSV α 4 gene or a translational start site for an HSV α 4 transcript. Particular antibodies are polyclonal sera against ICP4 or a monoclonal antibody against ICP4. The agent that inhibits ICP4 function may be administered prior to, concurrently with or after the administration of the agent that inhibits U_S3 function.

In yet another embodiment, there is provided a method for treating a subject with an HSV infection comprising the step of inhibiting HSV US3 function. The inhibition may comprise providing to the subject a first pharmaceutical composition comprising an HSV U_S3

antisense construct or a monoclonal antibody that binds immunologically to an HSV U_S3 polypeptide. The first pharmaceutical composition may be applied topically to HSV infected cells in said patient. The method may further comprise the step of providing to said subject a second pharmaceutical composition comprising a conventional anti-HSV agent, such as acyclovir. Acyclovir is delivered via a route selected from the group consisting of topically, orally and intravenously.

In a further aspect of the present invention the method for treating a subject with an HSV infection may further comprise the step of inhibiting HSV ICP4 function. The inhibition may comprise providing to the subject a first pharmaceutical composition comprising an HSV α 4 antisense construct or a monoclonal antibody that binds immunologically to an HSV ICP4 polypeptide. The first pharmaceutical composition may be applied topically to HSV infected cells in said patient. The method may further comprise the step of providing to said subject a second pharmaceutical composition comprising a conventional anti-HSV agent, such as acyclovir. Acyclovir is delivered via a route selected from the group consisting of topically, orally and intravenously.

In yet still another embodiment, there is provided a screening method for compounds having inhibitory activity against HSV U_S3 polypeptide-induced inhibition of apoptosis comprising the steps of (a) providing a first cell comprising an HSV US3 gene under the control of an HSV immediate early promoter; (b) infecting said first cell with a herpes simplex virus that lacks a functional U_S3 gene; (c) contacting said first cell with a test compound; (d) incubating said first cell under conditions permitting viral replication; and (e) comparing the cell pathology of said first cell following incubation with the cell pathology of a second cell that lacks an HSV U_S3 gene following infection with said herpes simplex virus and the cell pathology of a third cell comprising an HSV U_S3 gene under the control of an HSV immediate early promoter following infection with said herpes simplex virus but in the absence of said test compound. Cell pathology comprises condensation of chromatin, obliteration of nuclear membranes, vacuolization, cytoplasmic blebbing and DNA fragmentation.

The screening method may employ a cell line which contains an integrated copy of a wild-type HSV U_S3 gene under the control of an α 4 promoter and a herpes simplex virus that lacks a functional HSV U_S3 gene has a deletion in both copies of the virally-encoded U_S3

genes. For example, the herpes virus may carry a temperature sensitive mutation in both copies of the virally-encoded U_S3 gene; incubation is at 39.5°C.

Another screening method for compounds having inhibitory activity against HSV U_S3-induced inhibition of apoptosis comprises the steps of (a) providing a first cell comprising an HSV U_S3 gene under the control of an inducible promoter; (b) inducing transcription from said promoter; (c) contacting said first cell with a test compound; (d) incubating said first cell under conditions expression of an HSV U_S3 polypeptide; and (e) comparing the cell pathology of said first cell following incubation with the cell pathology of a second cell not having an HSV U_S3 gene following induction and the cell pathology of a third cell comprising an HSV U_S3 gene under the control of an inducible promoter following induction but in the absence of said test compound.

Yet another screening method for compounds having inhibitory activity against HSV U_S3 polypeptide-induced inhibition of apoptosis comprises the steps of (a) providing a first cell; (b) infecting said first cell with a herpes simplex virus; (c) contacting said first cell with a test compound; (d) incubating said first cell under conditions permitting viral replication; and (e) comparing the cell pathology of said first cell following incubation with the cell pathology of a second cell treated with said test compound alone and the cell pathology of a third cell following infection with said herpes simplex virus but in the absence of said test compound.

In still yet a further embodiment, there is provided a method for expressing a polypeptide in a cell comprising the steps of (a) contacting a cell with a herpes virus vector encoding said polypeptide; (b) contacting said cell with an agent that blocks the transactivating function of U_S3 but does not block the apoptosis inhibiting function of U_S3.

In yet still another embodiment, there is provided a screening method for compounds having inhibitory activity against HSV ICP4 polypeptide-induced inhibition of apoptosis comprising the steps of (a) providing a first cell comprising an HSV α 4 gene under the control of an HSV immediate early promoter; (b) infecting said first cell with a herpes simplex virus that lacks a functional α 4 gene; (c) contacting said first cell with a test compound; (d) incubating said first cell under conditions permitting viral replication; and (e) comparing the cell pathology of said first cell following incubation with the cell pathology of a second cell that lacks an HSV α 4 gene following infection with said herpes simplex virus and the cell

pathology of a third cell comprising an HSV $\alpha 4$ gene under the control of an HSV immediate early promoter following infection with said herpes simplex virus but in the absence of said test compound. Cell pathology comprises condensation of chromatin, obliteration of nuclear membranes, vacuolization, cytoplasmic blebbing and DNA fragmentation.

5 The screening method may employ a cell line which contains an integrated copy of a wild-type HSV $\alpha 4$ gene under the control of an $\alpha 4$ promoter and a herpes simplex virus that lacks a functional HSV $\alpha 4$ gene has a deletion in both copies of the virally-encoded $\alpha 4$ genes. For example, the herpes virus may carry a temperature sensitive mutation in both copies of the virally-encoded $\alpha 4$ gene; incubation is at 39.5°C.

10 Another screening method for compounds having inhibitory activity against HSV ICP4-induced inhibition of apoptosis comprises the steps of (a) providing a first cell comprising an HSV $\alpha 4$ gene under the control of an inducible promoter; (b) inducing transcription from said promoter; (c) contacting said first cell with a test compound; (d) incubating said first cell under conditions expression of an HSV ICP4 polypeptide; and (e) comparing the cell pathology of
15 said first cell following incubation with the cell pathology of a second cell not having an HSV $\alpha 4$ gene following induction and the cell pathology of a third cell comprising an HSV $\alpha 4$ gene under the control of an inducible promoter following induction but in the absence of said test compound.

20 Yet another screening method for compounds having inhibitory activity against HSV ICP4 polypeptide-induced inhibition of apoptosis comprises the steps of (a) providing a first cell; (b) infecting said first cell with a herpes simplex virus; (c) contacting said first cell with a test compound; (d) incubating said first cell under conditions permitting viral replication; and (e) comparing the cell pathology of said first cell following incubation with the cell pathology of a second cell treated with said test compound alone and the cell pathology of a third cell
25 following infection with said herpes simplex virus but in the absence of said test compound.

In still yet a further embodiment, there is provided a method for expressing a polypeptide in a cell comprising the steps of (a) contacting a cell with a herpes virus vector encoding said polypeptide; (b) contacting said cell with an agent that blocks the transactivating function of ICP4 but does not block the apoptosis inhibiting function of ICP4.

The present invention also provides a method for the identification of a candidate substance that is a modulator of US3-kinase activity comprising the steps of (a) providing an enzyme composition comprising U_S3 protein kinase and a threonine/serine protein substrate; (b) contacting the composition with the candidate substance under conditions that allow phosphorylation; (c) determining the phosphorylation of the threonine/serine substrate; and (d) comparing the phosphorylation of the threonine/serine substrate with the phosphorylation of the threonine/serine substrate in the absence of a candidate inhibitor substance; wherein an increase in phosphorylation is indicative of the candidate substance being a stimulator of phosphorylation and a decrease in phosphorylation of the threonine/serine substrate is indicative of the candidate being an inhibitor of phosphorylation.

The present invention further provides an inhibitor of U_S3-kinase activity identified according to a method comprising the steps of (a) providing an enzyme composition comprising U_S3 protein kinase and a threonine/serine protein substrate; (b) contacting the composition with the candidate substance under conditions that allow phosphorylation; (c) determining the phosphorylation of the threonine/serine substrate; and (d) comparing the phosphorylation of the threonine/serine substrate with the phosphorylation of the threonine/serine substrate in the absence of a candidate inhibitor substance; wherein a decrease in phosphorylation of the threonine/serine substrate is indicative of the candidate being an inhibitor of phosphorylation.

In another embodiments there is provided a stimulator of U_S3-kinase activity identified according to a method comprising the steps of (a) providing an enzyme composition comprising U_S3 protein kinase and a threonine/serine protein substrate; (b) contacting said composition with said candidate substance under conditions that allow phosphorylation; (c) determining the phosphorylation of said threonine/serine substrate; and (d) comparing the phosphorylation of said threonine/serine substrate with the phosphorylation of said threonine/serine substrate in the absence of a candidate inhibitor substance; wherein an increase in phosphorylation is indicative of said candidate substance being a stimulator of phosphorylation.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed

description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

5

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

10

FIG. 1: Diagrammatic representation of the HSV-1 genome showing the location of the $\alpha 4$ and U_L29 genes encoding ICP4 and ICP8, respectively. The reiterated sequences (open rectangles) flanking the unique short (U_S) and unique long (U_L) sequences (thin lines) and the location and direction of genes are as shown. Because the $\alpha 4$ gene maps within inverted repeats flanking the U_L , it is present in two copies per genome. The hatched lines within the rectangles indicates the position of the sequences deleted from the d120 mutant (DeLuca, *et al.*, 1985).

15

FIG. 2. Photograph of an agarose gel stained with ethidium bromide. Vero cells were mock-infected (lane 1), infected with HSV-1(F) (lane 2), HSV-1 d120 mutant (lane 3), HSV-1 120FR mutant (lane 4), or HSV-1 120KR mutant (lane 5). 30 hr post infection, 2×10^6 cells per sample were collected, washed in PBS, lysed in a solution containing 10 mM Tris-HCl, pH 8.0, 10 mM EDTA, and 0.5% Triton X-100, and centrifuged at 12,000 rpm for 25 min in an Eppendorf microcentrifuge to pellet chromosomal DNA. Supernatant fluids were digested with 0.1 mg RNase A per ml at 37°C for 1 hr and then for 2 hr with 1 mg proteinase K per ml at 50°C in the presence of 1% sodium dodecylsulphate (SDS), extracted with phenol and chloroform, and precipitated in cold ethanol and subjected to electrophoresis on horizontal 1.5% agarose gels containing 5 μ g of ethidium bromide per ml. DNA was visualized by UV light transillumination. Photographs were taken with the aid of a computer-assisted image processor (Eagle Eye II, Stratagene).

20

25

FIG. 3. Photograph of an agarose gel stained with ethidium bromide. Vero cells were mock-infected (lane 1), infected with HSV-1 120FR mutant (lane 2), wild-type HSV-1(F) (lane

3), HSV-1 R325 mutant (lane 4), or HSV-1 R7041 mutant (lane 5). Cells were harvested and processed as described in the legend to FIG. 2.

FIG. 4. Photograph of an agarose gel stained with ethidium bromide. Vero cells were infected with HSV-1(F) (lane 1), HSV-1 120FR mutant (lane 2), HSV-1 R7041 mutant (lane 3), HSV-1 R7306 mutant (lane 4), or double-infected with HSV-1 120FR and R7041 mutants (lane 5), HSV-1 d120 and 120FR mutants (lane 6), or HSV-1 120FR and R7306 mutants (lane 7). Cells were harvested and processed as described in the legend to FIG. 2.

FIG. 5. BHK-C13 cells were infected at a multiplicity of 10 pfu/cell with the indicated viruses. At 13 hr post infection cells were incubated in phosphate-free medium for 1 hr and then labeled with ^{32}P i for 4 hr. Cell lysates were electrophoretically separated in SDS polyacrylamide gels and electrically transferred onto nitrocellulose filters. Filters were exposed to film or probed with a $\text{U}_\text{L}34$ antibody.

DETAILED DESCRIPTION OF THE INVENTION

The identification of novel proteins having apoptotic activities and uses will provide important new tools for those working with the challenge of treatment and prevention of HSV infection. The present invention provides methods for the use of $\text{U}_\text{S}3$ gene and its gene product as inhibitors of apoptosis.

The herpes simplex virus 1 (HSV-1) mutant, which lacks the major regulatory gene designated $\alpha 4$, induced apoptosis, whereas in cells infected with wild-type virus, apoptosis did not ensue (Leopardi and Roizman, 1996). The inventors also reported that wild type virus blocked apoptosis induced by thermal shock. Recent studies by Koyama and Miwa (1997) and also in the inventors' laboratory demonstrated that the virus also blocks the induction of apoptosis by osmotic shock. These studies suggested that a functional $\alpha 4$ gene was necessary to block apoptosis but did not address the question of sufficiency. This led the inventors to design several studies that included the rescue of the deleted $\alpha 4$ genes in the mutant virus.

The inventors discovered that the mutant lacking the $\alpha 4$ gene, HSV-1(KOS)d120, had a secondary mutation in the gene $\text{U}_\text{S}3$ specifying a protein kinase. Thus, the inventors have discovered that a functional $\text{U}_\text{S}3$ is required in order to block apoptosis. This important finding

may now be exploited in the inhibition of apoptosis, the induction of apoptosis, as described herein below. Further, the present invention allows for the provision of methods for the use of agents that inhibit U_S3 and the U_S3 gene in order to induce apoptosis in HSV infected cells and for the identification of agents that inhibit the apoptosis-inhibiting function of ICP4. These and other related aspects of the present invention are described in further detail herein below.

I. *Herpes Simplex Virus*

Herpes simplex viruses, designated with subtypes 1 and 2, are enveloped viruses that are among the most common infectious agents encountered by humans, infecting millions of human subjects worldwide. These viruses cause a broad spectrum of disease which ranges from relatively insignificant to severe and life-threatening. The clinical outcome of herpes infections is dependent upon early diagnosis and prompt initiation of antiviral therapy. Despite some successful efforts in treating HSV infectious, dermal and epidermal lesion often recur, and HSV infections of neonates and infections of the brain are associated with high morbidity and mortality.

The large, complex, double-stranded DNA genome encodes dozens of different gene products, some of which derive from spliced transcripts. In addition to virion and envelope structural components, the virus encodes numerous other proteins including a protease, a ribonucleotides reductase, a DNA polymerase, a ssDNA binding protein, a helicase/primase, a DNA dependent ATPase, a dUTPase and others.

HSV genes form several groups whose expression is coordinately regulated and sequentially ordered in a cascade fashion (Honess and Roizman, 1974; Honess and Roizman 1975; Roizman and Sears, 1996). The expression of α genes, the first set of genes to be expressed after infection, is enhanced by the virion protein number 16, or α -transinducing factor (Post *et al.*, 1981; Batterson and Roizman, 1983; Campbell, *et al.*, 1984). The expression of β genes requires functional α gene products, most notably ICP4, which is encoded by the α 4 gene (DeLuca *et al.*, 1985). γ genes, a heterogeneous group of genes encoding largely virion structural proteins, require the onset of viral DNA synthesis for optimal expression (Holland *et al.*, 1980).

In line with the complexity of the genome, the life cycle of HSV is quite involved. In addition to the lytic cycle, which results in synthesis of virus particles and, eventually, cell death, the virus has the capability to enter a latent state in which the genome is maintained in neural ganglia until some as of yet undefined signal triggers a recurrence of the lytic cycle.

5

II. *The ICP4 Polypeptide*

As stated above, the expression of β genes is regulated in a major fashion by ICP4 (DeLuca *et al.*, 1985), and therefore this gene has a distinct effect on viral DNA synthesis. γ genes, a heterogeneous group of genes encoding largely virion structural proteins, require the onset of viral DNA synthesis for optimal expression (Honess and Roizman, 1975; Holland *et al.*, 1980). ICP4 plays a key role in this process - cells infected with viruses carrying temperature sensitive mutations in the $\alpha 4$ gene and maintained at nonpermissive temperatures express largely α proteins (Dixon and Shaffer, 1980). Furthermore, studies involving shift-up of infected cells from permissive to nonpermissive temperatures have confirmed a key role for ICP4 throughout the viral reproductive cycle.

ICP4 acts both as a transactivator and as a repressor (Roizman and Sears, 1996). The response elements for the repressor functions of ICP4 are high affinity binding sites located in the proximity of transcription initiation sites of the genes repressed by the protein (Kristie and Roizman, 1986a, Kristie and Roizman, 1986b, Faber and Wilcox, 1986, Muller, 1987, Michael and Roizman, 1989, Michael and Roizman, 1993). The strength of repression is dependent on both the distance and stereoaxial alignment with the TATA box (Leopardi *et al.*, 1995, Kuddus *et al.*, 1995). Low affinity sites for binding of ICP4 have also been documented, but their function is less well understood (Kristie and Roizman, 1986a, Kristie and Roizman, 1986b, Michael *et al.*, 1988). The response elements thought to act in the transactivation of viral genes by ICP4 are not known, but mutations in ICP4 may affect repression and activation independently of each other (Shepard and DeLuca, 1991).

Thus, the repressor function of ICP4 is associated with the presence of high affinity sites located at or near the transcription initiation sites of several genes. The transactivating function has not been associated to specific binding to DNA although it has been shown that late viral gene expression requires the association of ICP4 with nascent viral DNA and several host (*e.g.*,

30

RNA polymerase II, Epstein Barr virus small nuclear RNA associated host protein) proteins and ICP22, a viral transcriptional factor (Leopardi *et al.*, 1997). Extensive studies with deletion mutants exemplified by HSV-1(KOS)d120 led DeLuca *et al.* (1985) to map distinct domains within the ICP4 proteins. Studies in the inventors' laboratory have shown that ICP4 is extensively modified post translationally by phosphorylation, ADP(ribosyl)ation, and nucleotidylation (Roizman and Sears, 1996). The expectation is that these modifications are not random effects by existing enzymes but that each post translational modification enhances or inactivates a specific function of the protein.

10 III. The U_S3 Polypeptide

HSV encodes two protein kinases expressed by the genes U_S3 and U_L13, respectively (reviewed in Roizman and Sears, 1996). Whereas U_L13 is packaged in the virion, U_S3 is not. Not all substrates of the U_S3 are known (Purves *et al.*, 1986; 1987; Leader *et al.*, 1991). The major substrate of U_S3 protein kinase is an intrinsic membrane protein exposed on the surface of infected cells and encoded by the U_L34 gene (Purves *et al.*, 1991; 1992). The U_L34 is phosphorylated by more than one kinase (Purves 1991, 1992). In the absence of U_S3 protein kinase, the U_L34 protein has an apparent M_r of 33,000 and associates with several cellular phosphoproteins whereas in wild type infected cells U_L34 has an apparent M_r of 30,000 and does not exhibit an association with the host proteins (Purves *et al.*, 1992).

20 The U_S3 protein kinase phosphorylates threonine/serine in the consensus sequence RRR-R/X-S/T-R/Y (SEQ ID NO:6) (Purves *et al.*, 1986; Leader *et al.*, 1991). In the case of U_L34, this was verified by mutagenesis of the threonine codon in the sequence encoding RRRRTRRSRE (SEQ ID NO:5) (Purves *et al.*, 1991; 1992). The apparent M_r of the mutant U_L34 protein was 33,000, that is, corresponding to the apparent M_r of the U_L34 protein in cells infected with a virus lacking the U_S3 gene.

25 The inventors predict that U_S3 blocks apoptosis by phosphorylating one or more proteins. As stated above, for ICP4 to be functional it needs to be phosphorylated, this leads the inventors to believe that one of the substrates of U_S3 protein kinase is ICP4 itself, among other, as yet unidentified, phosphoproteins.

The involvement of U_S3 protein kinase in blocking of apoptosis induced by infection, thermal or osmotic shocks suggests that HSV differs from other viruses in the mechanism by which it blocks the apoptosis as a host response to infection. Thus, U_S3 may be used to in control apoptosis independent of viral infection.

5 Accordingly, the present invention describes a novel functional aspect of the protein kinase U_S3 that was previously undisclosed is its ability to inhibit apoptosis. Further, the invention describes a novel functional aspect of ICP4 as an inhibitor of apoptosis. Apoptosis, or programmed cell death, is characterized by certain cellular events, including nuclear condensation, DNA fragmentation, cytoplasmic membrane blebbing and, ultimately,
10 irreversible cell death. Apoptosis is an energy-dependent event. For the purposes of this application, apoptosis will be defined as inducing one or more of these events. Thus, use of the term "U_S3" in this application encompasses polypeptides having the anti-apoptosis function of U_S3. These need not be wild-type U_S3. Likewise, the use of the term "ICP4" in this application encompasses polypeptides having the anti-apoptosis function of ICP4 and it need not be wild-type
15 ICP4.

This functional attribute is manifested, for example, in U_S3's or ICP4's ability, alone or in combination with one another, to protect cells from apoptosis triggered by modification of cellular physiology by other viral genes. This observation permits utilization of U_S3 or ICP4 alone or in combination with each other, in a number of ways that could not have been
20 predicted from the prior art. For example, according to the present invention, the production of HSV vectors or recombinant proteins from HSV vectors can be enhanced by increasing the apoptosis inhibiting function of U_S3 or ICP4 or both. When cells are infected with HSV, premature cell death can limit the titer of virus produced or the amount of recombinant protein synthesized. Similarly, U_S3 and ICP4 may prolong the life of the cells expressing human or
25 animal genes introduced into cells by viral vectors in order to correct genetic defect. If the cell can be sustained longer, the titer of the virus stocks and the amount of protein should increase.

U_S3 and ICP4 may be obtained according to various standard methodologies that are known to those of skill in the art. For example, antibodies specific for U_S3 or ICP4 may be used in immunoaffinity protocols to isolate the respective polypeptide from infected cells, in
30 particular, from infected cell lysates. Antibodies are advantageously bound to supports, such as

columns or beads, and the immobilized antibodies can be used to pull the U₅3 or ICP4 target out of the cell lysate.

Alternatively, expression vectors, rather than viral infections, may be used to generate the polypeptide of interest. A wide variety of expression vectors may be used, including viral
5 vectors. The structure and use of these vectors is discussed further, below. Such vectors may significantly increase the amount of U₅3 and/or ICP4 protein in the cells, and may permit less selective purification methods such as size fractionation (chromatography, centrifugation), ion exchange or affinity chromatograph, and even gel purification. Alternatively, the expression vector may be provided directly to target cells, again as discussed further, below.

10 U₅3, according to the present invention, may advantageously be cleaved into fragments for use in further structural or functional analysis, or in the generation of reagents such as U₅3-related polypeptides and U₅3-specific antibodies. This can be accomplished by treating purified or unpurified U₅3 with a peptidase such as endoproteinase glu-C (Boehringer, Indianapolis, IN). Treatment with CNBr is another method by which U₅3 fragments may be produced from natural
15 U₅3. Recombinant techniques also can be used to produce specific fragments of U₅3. It may be that the phosphorylating and apoptosis-inhibiting functions of U₅3 reside in distinct domains of the protein. If such is the case, the ability to make domain-specific reagents now has significance. For example, the ability to provide an apoptosis-inhibiting U₅3 fragment that does not phosphorylate viral genes may prove to be effective in extending the life of neurons expressing
20 compensatory or therapeutic genes from a viral vector.

Likewise ICP4, may advantageously be cleaved into fragments for use in further structural or functional analysis, or in the generation of reagents such as ICP4-related polypeptides and ICP4-specific antibodies. Because the transactivating and apoptosis-inhibiting functions of ICP4 appear to reside in distinct domains, the ability to make domain-specific reagents now has
25 significance. For example, the ability to provide an apoptosis-inhibiting ICP4 fragment that does not transactivate viral genes may prove to be effective in extending the life of neurons expressing compensatory or therapeutic genes from a viral vector.

It is expected that changes may be made in the sequence of U₅3 or ICP4 while retaining a molecule having the structure and function of the natural U₅3 or ICP4 respectively. For example,
30 certain amino acids may be substituted for other amino acids in a protein structure without

appreciable loss of interactive capacity with structures such as, for example, substrate-binding regions. These changes are termed "conservative" in the sense that they preserve the structural and, presumably, required functional qualities of the starting molecule. The importance of U_S3 variants is highlighted by the observation, discussed in the examples, that mutants lacking the α 4 gene also have an additional mutation in the US3 gene making it non-functional in apoptosis. The mutation in U_S3 was silent and would not have affected the studies carried out by DeLuca *et al.* (1985) since viral gene expression, including that of U_S3, requires a functional α 4 gene and apoptosis is a very late event. Even if a rescue had been done, it would not have detected the mutation in U_S3 unless the infected cell were probed for the U_S3 function.

The importance of ICP4 variants is highlighted by the observation that temperature sensitive (*ts*) mutants of ICP4 exist that are impaired in their ability to transactivate viral genes at elevated temperatures (above about 39°C), but retain the apoptosis inhibiting function associated with this polypeptide. Further exploration of this dichotomy should reveal significant information on the regions in which these functions lie. It has been shown that the transactivation domain of ICP4 lies between about residues 100 and 200, the DNA-binding domains lies between about residues 300 and 500, the nuclear localization domain lies between about residues 700 and 750 and the transactivation domain lies between about residues 750 and 1298.

Conservative amino acid substitutions generally are based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. An analysis of the size, shape and type of the amino acid side-chain substituents reveals that arginine, lysine and histidine are all positively charged residues; that alanine, glycine and serine are all a similar size; and that phenylalanine, tryptophan and tyrosine all have a generally similar shape. Therefore, based upon these considerations, arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine; are defined herein as equivalent.

In making such changes, the hydropathic index of amino acids also may be considered. Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics, these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7);

serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte & Doolittle, 1982). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

It also is understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the polypeptide created is intended for use in immunological embodiments, as in the present case. U.S. Patent 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, *i.e.*, with a biological property of the protein.

As detailed in U.S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate ($+3.0 \pm 1$); glutamate ($+3.0 \pm 1$); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 ± 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).

In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

Numerous scientific publications have been devoted to the prediction of secondary structure, and to the identification of epitopes, from analyses of amino acid sequences (Chou & Fasman, 1974a,b; 1978a,b; 1979). Any of these may be used, if desired, to supplement the teachings of Hopp in U.S. Patent 4,554,101. Moreover, computer programs are currently available to assist with predicting antigenic portions and epitopic core regions of proteins. Examples include those programs based upon the Jameson-Wolf analysis (Jameson & Wolf,

1988; Wolf *et al.*, 1988), the program PepPlot® (Brutlag *et al.*, 1990; Weinberger *et al.*, 1985), and other new programs for protein tertiary structure prediction (Fetrow & Bryant, 1993).

Two designations for amino acids are used interchangeably throughout this application, as is common practice in the art. Alanine = Ala (A); Arginine = Arg (R); Aspartate = Asp (D);
5 Asparagine = Asn (N); Cysteine = Cys (C); Glutamate = Glu (E); Glutamine = Gln (Q); Glycine = Gly (G); Histidine = His (H); Isoleucine = Ile (I); Leucine = Leu (L); Lysine = Lys (K); Methionine = Met (M); Phenylalanine = Phe (F); Proline = Pro (P); Serine = Ser (S); Threonine = Thr (T); Tryptophan = Trp (W); Tyrosine = Tyr (Y); Valine = Val (V).

In addition to the peptidyl compounds described herein, the inventors also contemplate
10 that other sterically similar compounds may be formulated to mimic the key portions of the peptide structure, called peptidomimetics. Mimetics are peptide-containing molecules which mimic elements of protein secondary structure. See, for example, Johnson *et al.* (1993). The underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly to orient amino acid side chains in such a way as to facilitate molecular interactions,
15 such as those of receptor and ligand.

Successful applications of the peptide mimetic concept have thus far focused on mimetics of β -turns within proteins. Likely β -turn structures within U_S3 and ICP4 can be predicted by computer-based algorithms as discussed above. Once the component amino acids of the turn are determined, mimetics can be constructed to achieve a similar spatial orientation of the essential
20 elements of the amino acid side chains, as discussed in Johnson *et al.*, *supra*.

IV. Nucleic Acids Encoding U_S3 and ICP4

Also contemplated by the present invention are nucleic acids encoding U_S3 and ICP4. The gene for US3 is given in SEQ ID NO:3. The gene for ICP4 is known as α 4 (SEQ ID NO:1).
25 The amino acid sequences for U_S3 and ICP4 encoded by these genes are given in SEQ ID NO:4 and SEQ ID NO:2, respectively. The full length genomic sequence of HSV is known and can be found in Genbank (Accession No. x14112); ICP4 is encoded by identical diploid genes inverted relative to each other, their coding sequences are located from nucleotide 131, 128 to 127, 232 and 147,104 to 151, 000. The US3 protein coding sequence is from nucleotide 135, 222 to 136, 667.
30 Because of the degeneracy of the genetic code, many other nucleic acids also may encode a given

U₅3 or a given ICP4. For example, four different three-base codons encode the amino acids alanine, glycine, proline, threonine and valine, while six different codons encode arginine, leucine and serine. Only methionine and tryptophan are encoded by a single codon. A table of amino acids and the corresponding codons is presented herein for use in such embodiments.

5

TABLE 1

<u>Amino Acids</u>			<u>Codons</u>						
Alanine	Ala	A	GCA	GCC	GCG	GCU			
Cysteine	Cys	C	UGC	UGU					
Aspartic acid	Asp	D	GAC	GAU					
Glutamic acid	Glu	E	GAA	GAG					
Phenylalanine	Phe	F	UUC	UUU					
Glycine	Gly	G	GGA	GGC	GGG	GGU			
Histidine	His	H	CAC	CAU					
Isoleucine	Ile	I	AUA	AUC	AUU				
Lysine	Lys	K	AAA	AAG					
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG	CUU	
Methionine	Met	M	AUG						
Asparagine	Asn	N	AAC	AAU					
Proline	Pro	P	CCA	CCC	CCG	CCU			
Glutamine	Gln	Q	CAA	CAG					
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGU	

TABLE 1 - Continued

<u>Amino Acids</u>				<u>Codons</u>				
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG	UCU
Threonine	Thr	T	ACA	ACC	ACG	ACU		
Valine	Val	V	GUA	GUC	GUG	GUU		
Tryptophan	Trp	W	UGG					
Tyrosine	Tyr	Y	UAC	UAU				

In order to generate any nucleic acid encoding U_S3 or ICP4, one need only refer to the preceding codon table. Substitution of the natural codon with any codon encoding the same amino acid will result in a distinct nucleic acid that encodes U_S3 or ICP4 or a variant thereof. As a practical matter, this can be accomplished by site-directed mutagenesis of an existing U_S3 or α 4 gene or *de novo* chemical synthesis of one or more nucleic acids.

The preceding observations regarding codon selection, site-directed mutagenesis and chemical synthesis apply with equal force to the discussion of substitutional mutants in the section of peptides. Normally, substitutional mutants are generated by site-directed changes in the nucleic acid designed to alter one or more codons of the coding sequence.

In order to express an U_S3 polypeptide, or an antisense U_S3 transcript, it is necessary to provide an U_S3 gene in an expression vehicle. Similarly to express an ICP4 polypeptide, or an antisense α 4 transcript, it is necessary to provide an α 4 gene in an expression vehicle. The appropriate nucleic acid can be inserted into an expression vector by standard subcloning techniques. For example, an *E. coli* or baculovirus expression vector is used to produce recombinant polypeptide *in vitro*. The manipulation of these vectors is well known in the art. In one embodiment, the protein is expressed as a fusion protein with β -gal, allowing rapid affinity purification of the protein. Examples of such fusion protein expression systems are the glutathione S-transferase system (Pharmacia, Piscataway, NJ), the maltose binding protein

system (NEB, Beverly, MA), the FLAG system (IBI, New Haven, CT), and the 6xHis system (Qiagen, Chatsworth, CA).

Some of these fusion systems produce recombinant protein bearing only a small number of additional amino acids, which are unlikely to affect the functional capacity of the recombinant protein. For example, both the FLAG system and the 6xHis system add only short sequences, both of which are known to be poorly antigenic and which do not adversely affect folding of the protein to its native conformation. Other fusion systems produce proteins where it is desirable to excise the fusion partner from the desired protein. In another embodiment, the fusion partner is linked to the recombinant protein by a peptide sequence containing a specific recognition sequence for a protease. Examples of suitable sequences are those recognized by the Tobacco Etch Virus protease (Life Technologies, Gaithersburg, MD) or Factor Xa (New England Biolabs, Beverly, MA).

Recombinant bacterial cells, for example *E. coli*, are grown in any of a number of suitable media, for example LB, and the expression of the recombinant polypeptide induced by adding IPTG to the media or switching incubation to a higher temperature. After culturing the bacteria for a further period of between 2 and 24 hours, the cells are collected by centrifugation and washed to remove residual media. The bacterial cells are then lysed, for example, by disruption in a cell homogenizer and centrifuged to separate the dense inclusion bodies and cell membranes from the soluble cell components. This centrifugation can be performed under conditions whereby the dense inclusion bodies are selectively enriched by incorporation of sugars such as sucrose into the buffer and centrifugation at a selective speed.

If the recombinant protein is expressed in the inclusion bodies, as is the case in many instances, these can be washed in any of several solutions to remove some of the contaminating host proteins, then solubilized in solutions containing high concentrations of urea (e.g. 8M) or chaotropic agents such as guanidine hydrochloride in the presence of reducing agents such as β -mercaptoethanol or DTT (dithiothreitol).

Under some circumstances, it may be advantageous to incubate the polypeptide for several hours under conditions suitable for the protein to undergo a refolding process into a conformation which more closely resembles that of the native protein. Such conditions generally include low protein concentrations less than 500 μ g/ml, low levels of reducing agent,

concentrations of urea less than 2 M and often the presence of reagents such as a mixture of reduced and oxidized glutathione which facilitate the interchange of disulphide bonds within the protein molecule.

The refolding process can be monitored, for example, by SDS-PAGE or with antibodies which are specific for the native molecule (which can be obtained from animals vaccinated with the native molecule isolated from parasites). Following refolding, the protein can then be purified further and separated from the refolding mixture by chromatography on any of several supports including ion exchange resins, gel permeation resins or on a variety of affinity columns.

In yet another embodiment, the expression system used is one driven by the baculovirus polyhedron promoter. The gene encoding the protein can be manipulated by standard techniques in order to facilitate cloning into the baculovirus vector. A preferred baculovirus vector is the pBlueBac vector (Invitrogen, Sorrento, CA). The vector carrying the gene of interest is transfected into *Spodoptera frugiperda* (Sf9) cells by standard protocols, and the cells are cultured and processed to produce the recombinant protein.

There also are a variety of eukaryotic vectors that provide a suitable vehicle in which recombinant polypeptide can be produced. HSV itself has been used in tissue culture to express a large number of exogenous genes as well as for high level expression of its endogenous genes. For example, the chicken ovalbumin gene has been expressed from HSV using an α promoter. Herz and Roizman (1983). The *lacZ* gene also has been expressed under a variety of HSV promoters.

In an alternative embodiment, the nucleic acids employed actually may encode antisense constructs that hybridize, under intracellular conditions, to an U₅3 nucleic acid or an α 4 nucleic acid. The term "antisense construct" is intended to refer to nucleic acids, preferably oligonucleotides, that are complementary to the base sequences of a target DNA or RNA. Antisense oligonucleotides, when introduced into a target cell, specifically bind to their target nucleic acid and interfere with transcription, RNA processing, transport, translation and/or stability.

Antisense constructs may be designed to bind to the promoter and other control regions, exons, introns or even exon-intron boundaries of a gene. Antisense RNA constructs, or DNA encoding such antisense RNA's, may be employed to inhibit gene transcription or translation or both within a host cell, either *in vitro* or *in vivo*, such as within a host animal, including a human subject. Nucleic acid sequences which comprise "complementary nucleotides" are those which are capable of base-pairing according to the standard Watson-Crick complementarity rules. That is, that the larger purines will base pair with the smaller pyrimidines to form combinations of guanine paired with cytosine (G:C) and adenine paired with either thymine (A:T), in the case of DNA, or adenine paired with uracil (A:U) in the case of RNA. Inclusion of less common bases such as inosine, 5-methylcytosine, 6-methyladenine, hypoxanthine and others in hybridizing sequences does not interfere with pairing.

As used herein, the term "complementary" means nucleic acid sequences that are substantially complementary over their entire length and have very few base mismatches. For example, nucleic acid sequences of fifteen bases in length may be termed complementary when they have a complementary nucleotide at thirteen or fourteen positions with only a single mismatch. Naturally, nucleic acid sequences which are "completely complementary" will be nucleic acid sequences which are entirely complementary throughout their entire length and have no base mismatches.

Other sequences with lower degrees of homology also are contemplated. For example, an antisense construct which has limited regions of high homology, but also contains a non-homologous region (*e.g.*, a ribozyme) could be designed. These molecules, though having less than 50% homology, would bind to target sequences under appropriate conditions.

While all or part of the gene sequence of interest may be employed in the context of antisense construction, short oligonucleotides are easier to make and increase *in vivo* accessibility. However, both binding affinity and sequence specificity of an antisense oligonucleotide to its complementary target increases with increasing length. It is contemplated that antisense oligonucleotides of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or more base pairs will be used. One can readily determine whether a given antisense nucleic acid is effective at targeting of the corresponding host cell gene simply by testing the constructs *in vitro* to determine whether the endogenous gene's function is

affected or whether the expression of related genes having complementary sequences is affected.

In certain embodiments, one may wish to employ antisense constructs which include other elements, for example, those which include C-5 propyne pyrimidines. Oligonucleotides
5 which contain C-5 propyne analogues of uridine and cytidine have been shown to bind RNA with high affinity and to be potent antisense inhibitors of gene expression (Wagner *et al.*, 1990).

Throughout this application, the term "expression construct" is meant to include any type of genetic construct containing a nucleic acid coding for a gene product in which part or all
10 of the nucleic acid encoding sequence is capable of being transcribed. The transcript may be translated into a protein, but it need not be. Thus, in certain embodiments, expression includes both transcription of a gene and translation of a RNA into a gene product. In other embodiments, expression only includes transcription of the nucleic acid, for example, to generate antisense constructs.

15 In preferred embodiments, the nucleic acid is under transcriptional control of a promoter. A "promoter" refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene. The phrase "under transcriptional control" means that the promoter is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and
20 expression of the gene.

The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II. Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units. These
25 studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins.

At least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a

TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.

Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.

The particular promoter that is employed to control the expression of a nucleic acid is not believed to be critical, so long as it is capable of expressing the nucleic acid in the targeted cell. Thus, where a human cell is targeted, it is preferable to position the nucleic acid coding region adjacent to and under the control of a promoter that is capable of being expressed in a human cell. Generally speaking, such a promoter might include either a human or viral promoter. Preferred promoters include those derived from HSV, including the U_S3, or the α 4 promoter. Another preferred embodiment is the tetracycline controlled promoter.

In various other embodiments, the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter and the Rous sarcoma virus long terminal repeat can be used to obtain high-level expression of transgenes. The use of other viral or mammalian cellular or bacterial phage promoters which are well-known in the art to achieve expression of a transgene is contemplated as well, provided that the levels of expression are sufficient for a given purpose. Tables 2 and 3 list several elements/promoters which may be employed, in the context of the present invention, to regulate the expression of a transgene. This list is not intended to be exhaustive of all the possible elements involved in the promotion of transgene expression but, merely, to be exemplary thereof.

Enhancers were originally detected as genetic elements that increased transcription from a promoter located at a distant position on the same molecule of DNA. This ability to act over a large distance had little precedent in classic studies of prokaryotic transcriptional regulation.

Subsequent work showed that regions of DNA with enhancer activity are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins.

The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter must have one or more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities. Promoters and enhancers are often overlapping and contiguous, often seeming to have a very similar modular organization.

Additionally any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of a transgene. Use of a T3, T7 or SP6 cytoplasmic expression system is another possible embodiment. Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.

TABLE 2

PROMOTER
Immunoglobulin Heavy Chain
Immunoglobulin Light Chain
T-Cell Receptor
HLA DQ α and DQ β
β -Interferon
Interleukin-2
Interleukin-2 Receptor
MHC Class II 5
MHC Class II HLA-DR α
β -Actin

TABLE 2 - Continued

PROMOTER
Muscle Creatine Kinase
Prealbumin (Transthyretin)
Elastase I
Metallothionein
Collagenase
Albumin Gene
α -Fetoprotein
τ -Globin
β -Globin
c-fos
c-HA-ras
Insulin
Neural Cell Adhesion Molecule (NCAM)
α_1 -Antitrypsin
H2B (TH2B) Histone
Mouse or Type I Collagen
Glucose-Regulated Proteins (GRP94 and GRP78)
Rat Growth Hormone
Human Serum Amyloid A (SAA)
Troponin I (TN I)
Platelet-Derived Growth Factor
Duchenne Muscular Dystrophy
SV40
Polyoma
Retroviruses
Papilloma Virus
Hepatitis B Virus

TABLE 2 - Continued

PROMOTER
Human Immunodeficiency Virus
Cytomegalovirus
Gibbon Ape Leukemia Virus

TABLE 3

Element	Inducer
MT II	Phorbol Ester (TPA) Heavy metals
MMTV (mouse mammary tumor virus)	Glucocorticoids
β -Interferon	poly(rl)X poly(rc)
Adenovirus 5 E2	Ela
c-jun	Phorbol Ester (TPA), H ₂ O ₂
Collagenase	Phorbol Ester (TPA)
Stromelysin	Phorbol Ester (TPA), IL-1
SV40	Phorbol Ester (TPA)
Murine MX Gene	Interferon, Newcastle Disease Virus
GRP78 Gene	A23187
α -2-Macroglobulin	IL-6
Vimentin	Serum
MHC Class I Gene H-2kB	Interferon
HSP70	Ela, SV40 Large T Antigen
Proliferin	Phorbol Ester-TPA
Tumor Necrosis Factor	FMA
Thyroid Stimulating Hormone α Gene	Thyroid Hormone

Use of the baculovirus system will involve high level expression from the powerful polyhedron promoter.

One will typically include a polyadenylation signal to effect proper polyadenylation of the transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be employed. Preferred
5 embodiments include the SV40 polyadenylation signal and the bovine growth hormone polyadenylation signal, convenient and known to function well in various target cells. Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.

10 A specific initiation signal also may be required for efficient translation of coding sequences. These signals include the ATG initiation codon and adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be "in-frame"
15 with the reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be either natural or synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements (Bittner *et al.*, 1987).

20 In various embodiments of the invention, the expression construct may comprise a virus or engineered construct derived from a viral genome. The ability of certain viruses to enter cells via receptor-mediated endocytosis and to integrate into host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign genes into mammalian cells (Ridgeway, 1988; Nicolas and Rubenstein, 1988; Baichwal and Sugden, 1986; Temin, 1986). The first viruses used as vectors were DNA viruses including the
25 papovaviruses (simian virus 40, bovine papilloma virus, and polyoma) (Ridgeway, 1988; Baichwal and Sugden, 1986) and adenoviruses (Ridgeway, 1988; Baichwal and Sugden, 1986) and adeno-associated viruses. Retroviruses also are attractive gene transfer vehicles (Nicolas and Rubenstein, 1988; Temin, 1986) as are vaccinia virus (Ridgeway, 1988) and adeno-associated virus (Ridgeway, 1988). Such vectors may be used to (i) transform cell lines *in vitro*

for the purpose of expressing proteins of interest or (ii) to transform cells *in vitro* or *in vivo* to provide therapeutic polypeptides in a gene therapy scenario.

In a preferred embodiment, the vector is HSV. Because HSV is neurotropic, it has generated considerable interest in treating nervous system disorders. Moreover, the ability of HSV to establish latent infections in non-dividing neuronal cells without integrating into the host cell chromosome or otherwise altering the host cell's metabolism, along with the existence of a promoter that is active during latency. And though much attention has focused on the neurotropic applications of HSV, this vector also can be exploited for other tissues.

Another factor that makes HSV an attractive vector is the size and organization of the genome. Because HSV is large, incorporation of multiple genes or expression cassettes is less problematic than in other smaller viral systems. In addition, the availability of different viral control sequences with varying performance (temporal, strength, *etc.*) makes it possible to control expression to a greater extent than in other systems. It also is an advantage that the virus has relatively few spliced messages, further easing genetic manipulations.

HSV also is relatively easy to manipulate and can be grown to high titers. Thus, delivery is less of a problem, both in terms of volumes needed to attain sufficient MOI and in a lessened need for repeat dosings. For a review of HSV as a gene therapy vector, see Glorioso *et al.*, 1995.

V. Methods for Screening

A. *Inhibitors of U_S3 and ICP4 Anti-Apoptotic Activity*

In one embodiment of the present invention, there are provided methods of screening compounds for activity against U_S3's anti-apoptotic activity. These screening methods will determine the cell pathology of target cells that express U_S3, both in the presence and absence of the test compound. In another embodiment, the present invention, provides methods of screening compounds for activity against ICP4's anti-apoptotic activity. At least three different assays may be employed, as discussed below.

First, one may look at DNA fragmentation using a separative method, *e.g.*, chromatography or electrophoresis, to size fractionate the sample. As described in greater

detail in the examples, an exemplary assay involves the isolation of DNA from cells, followed by agarose gel electrophoresis and staining with ethidium bromide. DNA fragmentation, characteristic of apoptosis, will be visualized as "ladders" containing a wide range of fragment sizes.

5 Second, one may employ terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labeling (TUNEL) assays to measure the integrity of DNA (Gorczyca, 1993). This assay measures the fragmentation of DNA by monitoring the incorporation of labeled UTP into broken DNA strands by the enzyme terminal transferase. The incorporation can be monitored by electrospectroscopy or by cell sorting methodologies (*e.g.*, FACS)

10 Third, one may examine cells using standard light or electron microscopy to assess the presence or absence of the cytopathologies characteristic of apoptosis. Those of skill in the art, applying standard methods of microscopy, will be able to assess cytopathology.

In each of these assays, a cell will be employed as the target for induction and inhibition of apoptosis. In one embodiment, the cell will be infected with HSV that expresses its own U_S3 protein. In a second embodiment, the cell will carry the U_S3 gene linked to a viral promoter. Infection with the appropriate virus will result in stimulation of the U_S3 gene and expression of U_S3. In these first two embodiments, the infection should induce apoptosis in the cell, and the expression of U_S3 should limit this effect. In a third embodiment, the cell will contain, as part of its own genetic material, an inducible version of the U_S3 gene (*i.e.*, U_S3 linked to an inducible promoter). In this situation, it will be necessary to induce apoptosis via some other mechanism, such as hypothermia, osmotic shock or ICP4 expression, and express U_S3 by inducing the promoter. The present invention may further employ ICP4 alone or in combination with U_S3 in any of the embodiments described above.

25 The cell is contacted with a candidate inhibitor substance in order to assess its effect on U_S3 activity. The substance may be contacted with the cell prior to, at the same time, or after the provision of U_S3. In some cases, the candidate inhibitor substance may be contacted with the cell directly. In other situations, depending on the nature and putative mechanism of action, the candidate inhibitor substance may be reformulated to provide improved uptake. For example, where antisense oligonucleotides are provided, these may advantageously be formulated in liposomes or as virally-encapsulated expression vehicles. Where polypeptides

30

are to be tested, it may be advantageous to provide expression vectors encoding these molecules rather than the polypeptides themselves. Essentially, the most reasonable mechanism for delivering an effective amount of the candidate inhibitor substance to the proper intracellular site will be chosen. "Effective amount," for the purposes of the screening assay, is intended to mean an amount that will cause a detectable difference, and preferably a significant difference, in the cytopathology of the cell as compared to a similar treatment of the cell without the candidate inhibitor substance. A similar protocol may be used to test the effect of a candidate substance on ICP4 activity.

Once the candidate inhibitor substance has been provided to a cell that expresses the relevant peptide(s) (U_S3, ICP4 or both), the evaluation of cytopathology may be undertaken. Depending on the type of assay used to examine cytopathology, it is possible to automate this process and test hundreds of candidates at the same time. For example, 96-well trays may be employed in which several wells are reserved for controls while the remainder comprise test substances, usually with each substance being tested at several different amounts.

B. Screening for Modulators of US3 function

In certain embodiments, the present invention concerns a method for identifying modulators of U_S3 function. Such modulators may be inhibitors or stimulators of such a function. It is contemplated that this screening technique will prove useful in the general identification of any compound that will serve the purpose of inhibiting or stimulating U_S3-mediated kinase activity.

The active compounds may include fragments or parts of naturally-occurring compounds or may be only found as active combinations of known compounds which are otherwise inactive. However, prior to testing of such compounds in humans or animal models, it will possibly be necessary to test a variety of candidates to determine which have potential.

Accordingly, in screening assays to identify pharmaceutical agents which modulate U_S3 kinase activity, it is proposed that compounds isolated from natural sources, such as animals, bacteria, fungi, plant sources, including leaves and bark, and marine samples may be assayed as candidates for the presence of potentially useful pharmaceutical agents. It will be understood

that the pharmaceutical agents to be screened could also be derived or synthesized from chemical compositions or man-made compounds.

In these embodiments, the present invention is directed to a method for determining the ability of a candidate substance to inhibit or stimulate a protein kinase assay, the method including generally the steps of:

- (a) obtaining an enzyme composition comprising a protein kinase, preferably U_s3 protein kinase that is capable of phosphorylating threonine/serine residue;
- (b) admixing a candidate substance with the enzyme composition; and
- (c) determining the ability of the candidate substance to inhibit or stimulate threonine/serine phosphorylation

To identify a candidate substance as being capable of modulating protein phosphorylation, one would first obtain an enzyme composition that is capable of phosphorylating threonine/serine residues on a protein of interest. Naturally, one would measure or determine the phosphorylation activity of the threonine/serine kinase composition in the absence of the added candidate substance. One would then add the candidate substance to the threonine/serine kinase composition and re-determine the ability of the threonine/serine kinase composition to phosphorylate threonine/serine residues on a test protein in the presence of the candidate substance. A candidate substance which reduces the phosphorylation activity of the threonine/serine kinase composition relative to the activity in its absence is indicative of a candidate substance with inhibitor capability. Likewise, a candidate substance which increases the phosphorylation activity of the threonine/serine kinase composition relative to the activity in its absence is indicative of a candidate substance with stimulatory capability

The candidate screening assay is quite simple to set up and perform, after obtaining a relatively purified preparation of the enzyme, either from native or recombinant sources, one will admix a candidate substance with the enzyme preparation, under conditions which would allow the enzyme to perform its threonine/serine phosphorylation function but for inclusion of a candidate substance. In this fashion, one can measure the ability of the candidate substance to reduce or increase the threonine/serine phosphorylation activity relatively in the presence of the candidate substance.

"Effective amounts" in certain circumstances are those amounts effective to reproducibly reduce or increase threonine/serine kinase activity, or to inhibit or induce the apoptosis of cells, in comparison to their normal levels. Compounds that achieve significant appropriate changes in activity will be used. If desired, a battery of compounds may be
5 screened *in vitro* to identify agents for use in the present invention.

Significant decrease in threonine/serine phosphorylation, *e.g.*, as measured using immunoblotting techniques with anti-phosphorylation antibodies, are represented by a reduction in protein phosphorylation levels of at least about 30%-40%, and most preferably, by decreases of at least about 50%, with higher values of course being possible. Threonine/serine
10 kinase assays that measure threonine/serine phosphorylation are well known in the art and may be conducted *in vitro* or *in vivo*. Likewise increases in threonine/serine phosphorylation are represented by an increase in protein phosphorylation levels of at least about 30%-40%, and most preferably, by increases of at least about 50%, with higher values of course being possible.

15 Assays for apoptosis will measure certain cellular events, including nuclear condensation, DNA fragmentation, cytoplasmic membrane blebbing and, ultimately, irreversible cell death. The methodology for such measurements is well known to those of skill in the art. A significant alteration in apoptosis is represented by an increase or decrease of at least about 30%-40% as compared to normal, and most preferably, of at least about 50%, with
20 more significant increases or decreases also being possible. Therefore, if a candidate substance exhibited inhibition or induction of apoptosis in this type of study, it would likely be a suitable compound for use in the present invention.

Quantitative *in vitro* testing is not a requirement of the invention as it is generally envisioned that the candidate substance will often be selected on the basis of their known
25 properties or by structural and/or functional comparison to those agents already known to have an effect on threonine/serine kinases.

It will, of course, be understood that all the screening methods of the present invention are useful in themselves notwithstanding the fact that effective candidates may not be found. The invention provides methods for screening for such candidates, not solely methods of
30 finding them.

VI. Methods for the Inhibition of Apoptosis

In one embodiment of the present invention, there are provided methods for the inhibition of apoptosis in a cell. This is particularly useful where one seeks to immortalize a cell or, at a minimum, increase the longevity of a cell. This permits one to maintain that cell in culture for extended periods of time, perhaps indefinitely. Immortalized cells are useful primarily as factories for production of viral vectors or proteins of interest, but it also may be important to immortalize cell simply so that they may be studied *in vitro* with greater ease. In addition, though many viruses provide promise as gene therapeutic vectors, these vectors may trigger apoptosis in the cells they infect. Blocking virally-induced apoptosis will prevent cell death caused by these therapeutic vectors. As mentioned above, adenovirus, papilloma viruses, retrovirus, adeno-associated virus and HSV, for example, are candidate gene therapeutic vectors that could benefit from this application.

The general approach to inhibiting apoptosis, according to the present invention, will be to provide a cell with an U_S3 polypeptide, an ICP4 polypeptide or both, thereby permitting the inhibitory activity of U_S3, ICP4 or both to take effect. While it is conceivable that the protein may be delivered directly, a preferred embodiment involves providing a nucleic acid encoding the polypeptide, *i.e.*, an U_S3 gene, an α 4 gene or both, to the cell. Following this provision, the polypeptide is synthesized by the host cell's transcriptional and translational machinery, as well as any that may be provided by the expression construct. Cis-acting regulatory elements necessary to support the expression of the U_S3 or α 4 gene will be provided, as described above, in the form of an expression construct. It also is possible that, in the case of an HSV-infected cell, expression of the virally-encoded U_S3 or ICP4 could be stimulated or enhanced, or the expressed polypeptide stabilized, thereby achieving the same or similar effect.

In order to effect expression of constructs encoding U_S3 and/or ICP genes, the expression construct must be delivered into a cell. As described above in the discussion of viral vectors, one mechanism for delivery is via viral infection, where the expression construct is encapsidated in a viral particle which will deliver either a replicating or non-replicating nucleic acid. The preferred embodiment is an HSV vector, although virtually any vector would suffice. Similarly, where viral vectors are used to delivery other therapeutic genes, inclusion in these

vectors of an U₃ and/or $\alpha 4$ gene advantageously will protect the cell from virally induced apoptosis.

Several non-viral methods for the transfer of expression constructs into cultured mammalian cells also are contemplated by the present invention. These include calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe *et al.*, 1990) DEAE-dextran (Gopal, 1985), electroporation (Tur-Kaspa *et al.*, 1986; Potter *et al.*, 1984), direct microinjection (Harland and Weintraub, 1985), DNA-loaded liposomes (Nicolau and Sene, 1982; Fraley *et al.*, 1979) and lipofectamine-DNA complexes, cell sonication (Fechheimer *et al.*, 1987), gene bombardment using high velocity microprojectiles (Yang *et al.*, 1990), and receptor-mediated transfection (Wu and Wu, 1987; Wu and Wu, 1988). Some of these techniques may be successfully adapted for *in vivo* or *ex vivo* use, as discussed below.

In another embodiment of the invention, the expression construct may simply consist of naked recombinant DNA or plasmids. Transfer of the construct may be performed by any of the methods mentioned above which physically or chemically permeabilize the cell membrane. This is particularly applicable for transfer *in vitro*, but it may be applied to *in vivo* use as well. Another embodiment of the invention for transferring a naked DNA expression construct into cells may involve particle bombardment. This method depends on the ability to accelerate DNA coated microprojectiles to a high velocity allowing them to pierce cell membranes and enter cells without killing them (Klein *et al.*, 1987). Several devices for accelerating small particles have been developed. One such device relies on a high voltage discharge to generate an electrical current, which in turn provides the motive force (Yang *et al.*, 1990). The microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads.

In a further embodiment of the invention, the expression construct may be entrapped in a liposome. Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991). Also contemplated are lipofectamine-DNA complexes.

Liposome-mediated nucleic acid delivery and expression of foreign DNA *in vitro* has been very successful. Wong *et al.* (1980) demonstrated the feasibility of liposome-mediated delivery and expression of foreign DNA in cultured chick embryo, HeLa and hepatoma cells. In certain embodiments of the invention, the liposome may be complexed with a hemagglutinating virus (HVJ). This has been shown to facilitate fusion with the cell membrane and promote cell entry of liposome-encapsulated DNA (Kaneda *et al.*, 1989). In other embodiments, the liposome may be complexed or employed in conjunction with nuclear non-histone chromosomal proteins (HMG-1) (Kato *et al.*, 1991). In yet further embodiments, the liposome may be complexed or employed in conjunction with both HVJ and HMG-1. In other
5
10
embodiments, the delivery vehicle may comprise a ligand and a liposome. Where a bacterial promoter is employed in the DNA construct, it also will be desirable to include within the liposome an appropriate bacterial polymerase.

Other expression constructs which can be employed to deliver a nucleic acid encoding an U₃ and/or α 4 transgene into cells are receptor-mediated delivery vehicles. These take
15
advantage of the selective uptake of macromolecules by receptor-mediated endocytosis in almost all eukaryotic cells. Because of the cell type-specific distribution of various receptors, the delivery can be highly specific (Wu and Wu, 1993).

Receptor-mediated gene targeting vehicles generally consist of two components: a cell receptor-specific ligand and a DNA-binding agent. Several ligands have been used for
20
receptor-mediated gene transfer. The most extensively characterized ligands are asialoorosomucoid (ASOR) (Wu and Wu, 1987) and transferrin (Wagner *et al.*, 1990). Recently, a synthetic neoglycoprotein, which recognizes the same receptor as ASOR, has been used as a gene delivery vehicle (Ferkol *et al.*, 1993; Perales *et al.*, 1994). Mannose can be used to target the mannose receptor on liver cells. Also, antibodies to CD5 (CLL), CD22
25
(lymphoma), CD25 (T-cell leukemia) and MAA (melanoma) can similarly be used as targeting moieties. In other embodiments, the delivery vehicle may comprise a ligand and a liposome.

Primary mammalian cell cultures may be prepared in various ways. In order for the cells to be kept viable while *in vitro* and in contact with the expression construct, it is necessary to ensure that the cells maintain contact with the correct ratio of oxygen and carbon dioxide and

nutrients but are protected from microbial contamination. Cell culture techniques are well documented and are disclosed herein by reference (Freshner, 1992).

One embodiment of the foregoing involves the use of gene transfer to immortalize cells for the production of proteins. The gene for the protein of interest may be transferred as described above into appropriate host cells followed by culture of cells under the appropriate conditions. The gene for virtually any polypeptide may be employed in this manner. The generation of recombinant expression vectors, and the elements included therein, are discussed above. Alternatively, the protein to be produced may be an endogenous protein normally synthesized by the cell in question.

Examples of useful mammalian host cell lines are Vero and HeLa cells and cell lines of Chinese hamster ovary, W138, BHK, COS-7, 293, HepG2, 3T3, RIN and MDCK cells. In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and process the gene product in the manner desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins. Appropriate cell lines or host systems can be chosen to insure the correct modification and processing of the foreign protein expressed.

A number of selection systems may be used including, but not limited to, HSV thymidine kinase, hypoxanthine-guanine phosphoribosyltransferase and adenine phosphoribosyltransferase genes, in *tk-*, *hgpri-* or *aprt-* cells, respectively. Also, anti-metabolite resistance can be used as the basis of selection for *dhfr*, that confers resistance to; *gpt*, that confers resistance to mycophenolic acid; *neo*, that confers resistance to the aminoglycoside G418; and *hygro*, that confers resistance to hygromycin.

Animal cells can be propagated *in vitro* in two modes: as non-anchorage dependent cells growing in suspension throughout the bulk of the culture or as anchorage-dependent cells requiring attachment to a solid substrate for their propagation (*i.e.*, a monolayer type of cell growth).

Non-anchorage dependent or suspension cultures from continuous established cell lines are the most widely used means of large scale production of cells and cell products. However, suspension cultured cells have limitations, such as tumorigenic potential and lower protein production than adherent cells.

5 Large scale suspension culture of mammalian cells in stirred tanks is a common method for production of recombinant proteins. Two suspension culture reactor designs are in wide use - the stirred reactor and the airlift reactor. The stirred design has successfully been used on an 8000 liter capacity for the production of interferon (Phillips *et al.*, 1985; Mizrahi, 1983). Cells are grown in a stainless steel tank with a height-to-diameter ratio of 1:1 to 3:1. The culture is
10 usually mixed with one or more agitators, based on bladed disks or marine propeller patterns. Agitator systems offering less shear forces than blades have been described. Agitation may be driven either directly or indirectly by magnetically coupled drives. Indirect drives reduce the risk of microbial contamination through seals on stirrer shafts.

 The airlift reactor, also initially described for microbial fermentation and later adapted
15 for mammalian culture, relies on a gas stream to both mix and oxygenate the culture. The gas stream enters a riser section of the reactor and drives circulation. Gas disengages at the culture surface, causing denser liquid free of gas bubbles to travel downward in the downcomer section of the reactor. The main advantage of this design is the simplicity and lack of need for mechanical mixing. Typically, the height-to-diameter ratio is 10:1. The airlift reactor scales up
20 relatively easily, has good mass transfer of gases and generates relatively low shear forces.

VII. Methods for the Induction of Apoptosis

 In another embodiment of the present invention, there is contemplated the method of inducing apoptosis in HSV-infected cells, *i.e.*, blocking the apoptotic function of U_s3, ICP4 or
25 both. In this way, it may be possible to curtail viral infection by bringing about a premature death of the infected cell. In addition, it may prove effective to use this sort of therapeutic intervention in combination with more traditional chemotherapies, such as the administration acyclovir.

The general form that this aspect of the invention will take is the provision, to a cell, of an agent that will inhibit U₅3 function, ICP4 function or indeed inhibit the function of both. Four such agents are contemplated as outlined below.

First, one may employ an antisense nucleic acid that will hybridize either to the U₅3 gene or the U₅3 transcript, thereby preventing transcription or translation, respectively. Likewise, one may employ an antisense nucleic acid that will hybridize to an α 4 gene or an α 4 transcript. The considerations relevant to the design of antisense constructs have been presented above.

Second, one may utilize an U₅3-binding protein or peptide, for example, a peptidomimetic or an antibody that binds immunologically to an U₅3, the binding of either will block or reduce the activity of an U₅3. Again the same is true of ICP4 in that one may utilize an ICP4-binding protein or peptide, for example, a peptidomimetic or an antibody that binds immunologically to an ICP4, the binding of either resulting in a block or reduction of ICP4 activity. The methods of making and selecting peptide binding partners and antibodies are well known to those of skill in the art.

Third, one may provide to the cell an antagonist of U₅3 for example, the in the case of U₅3 phosphorylation target sequence, alone or coupled to another agent. Equally one may provide to the cell an antagonist of ICP4, for example, the transactivation target sequence, alone or coupled to another agent. And fourth, one may provide an agent that binds to the U₅3 or ICP4 target without the same functional result as would arise with U₅3 or ICP4 binding.

Provision of an U₅3 gene, an U₅3-binding protein, an U₅3 antagonist, or an α 4 gene, an ICP4-binding protein, or an ICP4 antagonist, would be according to any appropriate pharmaceutical route. The formulation of such compositions and their delivery to tissues is discussed below. The method by which the nucleic acid, protein or chemical is transferred, along with the preferred delivery route, will be selected based on the particular site to be treated. Those of skill in the art are capable of determining the most appropriate methods based on the relevant clinical considerations.

Many of the gene transfer techniques that generally are applied *in vitro* can be adapted for *ex vivo* or *in vivo* use. For example, selected organs including the liver, skin, and muscle

tissue of rats and mice have been bombarded *in vivo* (Yang *et al.*, 1990; Zelenin *et al.*, 1991). Naked DNA also has been used in clinical settings to effect gene therapy. These approaches may require surgical exposure of the tumor tissue or direct intratumoral injection. Nicolau *et al.* (1987) accomplished successful liposome-mediated gene transfer in rats after intravenous
5 injection.

Dubensky *et al.* (1984) successfully injected polyomavirus DNA in the form of CaPO_4 precipitates into liver and spleen of adult and newborn mice demonstrating active viral replication and acute infection. Benvenisty and Neshif (1986) also demonstrated that direct intraperitoneal injection of CaPO_4 precipitated plasmids results in expression of the transfected
10 genes. Thus, it is envisioned that DNA encoding an antisense construct also may be transferred in a similar manner *in vivo*.

Where the embodiment involves the use of an antibody that recognizes an U_s3 or an ICP4 polypeptide, consideration must be given to the mechanism by which the antibody is introduced into the cell cytoplasm. This can be accomplished, for example, by providing an
15 expression construct that encodes a single-chain antibody version of the antibody to be provided. Most of the discussion above relating to expression constructs for antisense versions of the respective genes will be relevant to this aspect of the invention. Alternatively, it is possible to present a bifunctional antibody, where one antigen binding arm of the antibody recognizes an U_s3 or ICP4 polypeptide and the other antigen binding arm recognizes a receptor
20 on the surface of the cell to be targeted. Examples of suitable receptors would be an HSV glycoprotein such as gB, gC, gD, or gH. In addition, it may be possible to exploit the Fc-binding function associated with HSV gE, thereby obviating the need to sacrifice one arm of the antibody for purposes of cell targeting.

Advantageously, one may combine this approach with more conventional
25 chemotherapeutic options. Acyclovir is an active agent against HSV-1 and HSV-2. The drug inhibits actively replicating herpes virus but is not active against latent virus. Acyclovir is available in three formulations. For topical use, a five percent ointment produces therapeutic drug levels in mucocutaneous lesions. For systemic use, acyclovir may be administered orally or intravenously. The usual intravenous dosage in adults with normal renal function is 5 mg/kg
30 infused at a constant rate over one hour and given every eight hours; this dosage produces peak

plasma levels at about 10 g/ml. For HSV encephalitis, twice this dose is used. The usual adult oral dosage is 200 mg, five times daily, which produces plasma levels that are less than 10% as high as those achieved with intravenous administration; even these levels are inhibitory to the virus, however. Acyclovir is given in an oral dosage of 800 mg five times daily for the treatment of herpes zoster, although oral administration generally is reserved for patients with severe symptoms. A three percent ophthalmic preparation produces inhibitory drug levels in the aqueous humor and is effective for herpes keratitis.

In contemplating combinatorial aspects of the present invention, it will be possible to combine the U₅3 therapeutic compositions of the present invention with other apoptosis inducing or inhibiting compositions. For example the present inventors have show that it is possible to affect apoptosis using compositions derived from ICP4 protein or polypeptide (SEQ ID NO:2) and the α 4 gene or gene constructs protein or polypeptide (SEQ ID NO:1). Thus in light of the teachings presented herein, it will be possible for one of ordinary skill in the art to combine the U₅3 therapeutic compositions with those derived from ICP4 and α 4 to affect apoptosis as described herein below.

To kill cells, inhibit cell growth, or induce apoptosis as defined above, using the methods and compositions of the present invention, one would generally contact a "target" cell with a U₅3 and/or an ICP4 expression construct alone or in combination with at least one other agent. These compositions would be provided in a combined amount effective to kill or induce apoptosis of the cell. This process may involve contacting the cells with the expression construct and the agent(s) or factor(s) at the same time. This may be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting the cell with two distinct compositions or formulations, at the same time, wherein one composition includes the expression construct and the other includes the agent.

Alternatively, the gene therapy treatment may precede or follow the other agent treatment by intervals ranging from minutes to weeks. In embodiments where the other agent and expression construct are applied separately to the cell, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the agent and expression construct would still be able to exert an advantageously combined effect on the cell. In such instances, it is contemplated that one would contact the cell with both modalities

within about 12-24 hours of each other and, more preferably, within about 6-12 hours of each other, with a delay time of only about 12 hours being most preferred. In some situations, it may be desirable to extend the time period for treatment significantly, however, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.

It also is conceivable that more than one administration of either U₅3 or the other agent will be desired. Various combinations may be employed, where U₅3 is "A" and the other agent is "B", as exemplified below:

A/B/A B/A/B B/B/A A/A/B B/A/A A/B/B B/B/B/A B/B/A/B

A/A/B/B A/B/A/B A/B/B/A B/B/A/A B/A/B/A B/A/A/B B/B/B/A

A/A/A/B B/A/A/A A/B/A/A A/A/B/A A/B/B/B B/A/B/B B/B/A/B

Other combinations are contemplated where ICP4 and α 4 may also be used. Again, to achieve apoptosis, both agents are delivered to a cell in a combined amount effective induce cell death.

The skilled artisan is directed to "Remington's Pharmaceutical Sciences" 15th Edition, chapter 33, in particular pages 624-652. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.

The inventors propose that the regional delivery of U₅3 expression constructs and/or ICP4 expression constructs to patients with HSV linked disease will be a very efficient method for delivering a therapeutically effective gene to counteract the clinical disease. Similarly, the chemotherapy may be directed to a particular, affected region of the subjects body. Alternatively, systemic delivery of expression construct and/or the agent may be appropriate in certain circumstances, for example, where extensive metastasis has occurred.

In addition to combining U₅3-targeted therapies with chemotherapies, it also is contemplated that combination with other gene therapies will be advantageous. For example,

targeting of U_S3 and α 4 mutations at the same time may produce an improved apoptotic treatment.

It also should be pointed out that any of the foregoing therapies may prove useful by themselves in treating a U_S3 related disease. In this regard, reference to chemotherapeutics and non-U_S3 gene therapy in combination should also be read as a contemplation that these approaches may be employed separately.

VIII. Methods for the Inhibition of Virus-Induced Cell Death *In Vivo*

In another embodiment of the present invention, there are provided methods for the inhibition of cell death induced *in vivo* by any cause comprising the provision of U_S3 polypeptides or U_S3 genes, or ICP4 polypeptides and α 4 genes or combinations of the two. Also contemplated in this aspect of the invention is the stimulation of viral U_S3 expression, and/or stimulation of viral ICP4 expression or stabilization of the virally-expressed U_S3 polypeptide and or ICP4 polypeptide. Though inhibition of apoptosis generally is thought of as advantageous to the virus, it may be desirable to effect this result as part of a method of treating a viral infection. For example, if the host cell remains viable, the virus may continue to replicate; alternatively, if apoptosis were occurring, the virus might be inclined to "go latent" in the neural ganglia, where chemotherapeutic intervention is not helpful. Thus, by preventing early death of the cell, U_S3 and/or ICP4 may cause the virus to remain susceptible to treatment where it otherwise would escape.

The mechanisms for delivering proteins and nucleic acids to a cell are discussed elsewhere in this document and need not be repeated here. The use of standard chemotherapeutics has been presented in the preceding section, and is incorporated in this section.

IX. Pharmaceuticals and *In Vivo* Methods for the Treatment of Disease

Aqueous pharmaceutical compositions of the present invention will have an effective amount of an U_S3 and/or α 4 expression construct, an antisense U_S3 and/or α 4 expression construct, an expression construct that encodes a therapeutic gene along with U_S3 and/or α 4, a protein that inhibits U_S3 and/or α 4 function, such as an anti-U_S3 antibody or an anti-ICP4

antibody, respectively, or an U_S3 polypeptide and/or an ICP4 polypeptide. Such compositions generally will be dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. An "effective amount," for the purposes of therapy, is defined at that amount that causes a clinically measurable difference in the condition of the subject. This amount will vary depending on the substance, the condition of the patient, the type of treatment, the location of the lesion, *etc.*

The phrases "pharmaceutically or pharmacologically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or human, as appropriate. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredients, its use in the therapeutic compositions is contemplated. Supplementary active ingredients, such as other anti-cancer agents, can also be incorporated into the compositions.

In addition to the compounds formulated for parenteral administration, such as those for intravenous or intramuscular injection, other pharmaceutically acceptable forms include, *e.g.*, tablets or other solids for oral administration; time release capsules; and any other form currently used, including cremes, lotions, mouthwashes, inhalants and the like.

The active compounds of the present invention will often be formulated for parenteral administration, *e.g.*, formulated for injection *via* the intravenous, intramuscular, subcutaneous, or even intraperitoneal routes. The preparation of an aqueous composition that contains glycosylceramide synthesis inhibitory compounds alone or in combination with a chemotherapeutic agent as active ingredients will be known to those of skill in the art in light of the present disclosure. Typically, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for using to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified.

Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.

Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or
5 dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In many cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.

10 The active compounds may be formulated into a composition in a neutral or salt form. Pharmaceutically acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases
15 such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.

The carrier also can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained,
20 for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.
25 Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by
30 incorporating the various sterilized active ingredients into a sterile vehicle which contains the

basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

In certain cases, the therapeutic formulations of the invention could also be prepared in forms suitable for topical administration, such as in cremes and lotions. These forms may be used for treating skin-associated diseases, such as various sarcomas. In certain other cases, the formulation will be geared for administration to the central nervous system, *e.g.*, the brain.

Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, with even drug release capsules and the like being employable.

For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could be dissolved in 1 mL of isotonic NaCl solution and either added to 1000 mL of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

X. Examples

The following examples are included to demonstrate preferred embodiments of the present invention. It should be appreciated by those of skill in the art that that techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred

modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar results without departing from the spirit and scope of the invention.

5

EXAMPLE 1:

Materials And Methods

Cells and Viruses. Vero and BHK cells were originally obtained from ATCC. HSV-1(F) is the prototype HSV-1 strain used in this laboratory (Ejercito *et al.*, 1967). In
10 recombinant R325 derived from HSV-1(F), approximately 800 bp comprising the carboxyl-terminal half of the $\alpha 4$ gene and grows only in a Vero cell line expressing the $\alpha 4$ gene (DeLuca *et al.*, 1985). Both the virus and the cell line were kind gifts of Neal DeLuca (University of Pittsburgh). The U_S3 gene was deleted from the recombinant R7041 (Longnecker *et al.*, 1987) and then repaired to yield R7306).

15

Plasmids and Cosmids. The plasmid pRB5166 was constructed by cloning into the SalI/BamHI sites of the pACYC184 vector a HSV-1 DNA fragment that extends from the Sal I site at + 177 with respect to the $\alpha 4$ gene transcription start site and includes the entire BamHI P and BamHI S fragments. The cosmid cloning vector pRB78 was constructed as follows. The multiple cloning site of the Stratagene SupercosI (La Jolla CA, cat#251301) was cleaved with
20 EcoRI and replaced with an oligonucleotides containing EcoRI/PacI/Sse8387I/SpeI/BamHI/NdeI/EcoRV/PacI/EcoRI cloning sites. The PacI restriction site, absent in HSV-1, serves to liberates the cloned HSV-1(F) DNA fragments from the vector. HSV-1(F) viral DNA was prepared from virions as previously described. To construct cosmid pBC1004, which contains the HSV-1(F) sequence n133052 through n17059, viral DNA was
25 partially digested with Sau3A I, dephosphorylated and ligated into the BamHI site of the pRB78 cosmid vector previously linearized with Xba I. The DNA was then packaged using Stratagene Gigapack XLII (La Jolla, CA), following the manufacturer's instructions. E. coli L-1 Blue MR was then infected and ampicillin-resistant colonies were screened by restriction enzyme analysis. Insert termini were sequenced to verify mapping. Cosmid pBC1008 was
30 constructed by cloning the BglII F-H fragment (HSV-1(F) n106750 through n142759) into the

*Bam*HI site of pBR78 vector. Cosmid pBC1009 was constructed as follows. An *Nsi*I/*Sca*I DNA fragment was isolated from a double digest of viral DNA. The fragment (HSV-1(F) n137538 through n18545) was ligated into the *Sse*8387I/*Eco*RV sites of pBR78. Cosmids PBC1008 and PBC1009 were mapped by restriction enzyme analysis and insert termini were
5 sequenced (FIG. 1).

Electron photomicroscopy. Vero cells infected with HSV-1(F) or d120 were incubated for 20 hrs at 37°C. Cells were fixed in 2% glutaraldehyde in PBS for 60 min at 4°C, post-fixed with 1% osmium tetroxide, en bloc stained with uranyl acetate (5mg/ml), dehydrated in acetone, and embedded in Epon 812. Thin sections were examined either unstained or poststained with
10 uranyl acetate and lead hydroxide. The cells were photographed at 6000 X in a Siemens 101 electron microscope.

Light photomicroscopy. Cells were labeled with biotinylated dUTP. At indicated times the cells were fixed in ice-cold methanol at -20°C and air-dried, then rinsed in phosphate buffered saline, reacted for 15 min at room temperature with 40 ml of a solution containing 1x terminal
15 transferase buffer (Promega), 1 mM CoCl₂, 0.05 mg/ml bovine serum albumin (BSA), 0.5 nmoles biotin-16-dUTP (Boehringer Mannheim Biochemicals) and 3 units of terminal transferase (TdT, Promega), rinsed extensively in PBS, reacted for 30 min at room temperature with 40 ml of a solution containing Texas red-conjugated avidin in 4x SSC (1x SSC is 0.15 M NaCl, 0.015 M Na-citrate), 0.1 % Triton X-100, 5% (w/v) nonfat dry milk, extensively rinsed with PBS, mounted
20 in 10% PBS in glycerol and examined under a Zeiss confocal fluorescence microscope. The images were captured under identical settings with the software provided by Zeiss and printed in a Tektronix 440 phaser printer. Cells were mock infected, 37°C, 20 hrs; infected with d120 virus, 37°C 20 hrs; infected with HSV-1(F), 37°C, 20 hrs; infected with d120 virus, 37°C 30 hrs; mock-infected, 39.5°C, 30 hrs.; infected with d120 virus, 39.5°C, 30 hrs.; and infected with HSV-1(F),
25 39.5° C, 30 hrs.

DNA Fragmentation Assay. Vero cells or E5 cells were infected with HSV-1(F), d120 mutant, or HSV-1 *ts*HA1 mutant and maintained at 37°C or 39.5°C in the absence or in the presence of phosphonoacetic acid. At 30 hrs after infection, 2 x 10⁶ cells per sample were collected, washed in PBS, lysed in a solution containing 10 mM Tris-HCl, pH 8.0, 10 mM EDTA,
30 and 0.5 % Triton X-100, and centrifuged at 12,000 rpm for 25 min in an Eppendorf

microcentrifuge to pellet chromosomal DNA. Supernatant fluids were digested with 0.1 mg RNase A per ml at 37°C for 1 hr, for 2 hrs with 1 mg proteinase K per ml at 50°C in the presence of 1 % sodium dodecylsulphate (SDS), extracted with phenol and chloroform, and precipitated in cold ethanol and subjected to electrophoresis on horizontal 1.5 % agarose gels containing 5 mg of ethidium bromide per ml. DNA was visualized by UV light transillumination. Photographs were taken with the aid of a computer-assisted image processor (Eagle Eye II, Stratagene).

Construction of recombinant viruses by marker rescue. Recombinant viruses were constructed using a modification of the technique originally described by Post and Roizman (1981). Vero cells were transfected with plasmid or cosmid DNA using Lipofectamin, according to the manufacturer's instructions. At 6 hr after transfection, the cells were exposed to 0.1 to 1 PFU of HSV-1(Kos)d120 per cell. Recombinant viruses were isolated from single plaques and grown in Vero cells. To obtain HSV-1 120KR, Vero cells were exposed to 10 PFU of HSV-1(KOS)d120 per cell. The infected cells were harvested at 48 hr post infection, frozen-thawed and sonicated, and then serially diluted and titered on Vero cells. Recombinant viruses were isolated from single plaques and grown in Vero cells.

EXAMPLE 2

An HSV-1 mutant deleted in ICP4 induces apoptosis.

In this series of studies, Vero cells infected with wild-type or the d120 mutant were examined for morphologic evidence of apoptosis. Vero cells were fixed and harvested at 20 to 24 hrs after infection with wild-type or d120, embedded, sectioned, and examined in a Siemens 101 electron microscope. The cells infected with wild-type virus showed typical infected cell morphology, *i.e.*, marginated chromatin, separation of inner and outer nuclear membranes, and accumulation of virus particles in some but not all cells. Cells infected with the d120 deletion mutant exhibited extensive condensation of chromatin, obliteration of the nuclear membrane, and extensive vacuolization and blebbing of the cytoplasm. It was estimated that approximately 40 to 50% of the infected cells exhibited some or all of the morphologic changes described above.

In another series of studies, Vero cells were mock-infected or infected with 10 PFU of either the wild-type or the d120 mutant virus per cell. After 20 hrs of incubation at 37° C the

cells were fixed, labeled with biotinylated dUTP in the presence of terminal transferase, and then reacted with fluorescent avidin. Mock-infected cells or cells infected with wild-type virus showed no sign of labeling with biotinylated dUTP by terminal transferase, whereas cells infected with d120 and maintained at the same temperature showed extensive fluorescence due to the reaction of fluorescent avidin to biotinylated dUTP incorporated at the DNA termini created by the cleavage of DNA.

In the third series of studies, replicate Vero cell cultures were infected with 10 PFU of either HSV-1(F) or d120 per cell and incubated at 37°C. The study also included a Vero cell culture infected with HSV-1(F), overlaid with medium containing 300 µg of phosphonoacetate per ml and incubated at 37°C, and a set of Vero cell cultures infected with 10 PFU of HSV-1 tsHA1 and incubated at either 37°C or 39.5°C. This concentration of phosphonoacetate completely inhibits viral DNA synthesis and blocks the expression of γ_2 genes dependent on viral synthesis for their expression. The cells were harvested at 30 hrs after infection, lysed, and centrifuged to pellet the chromosomal DNA. The supernatant fluids were processed as described above and subjected to electrophoresis in agarose gels to test for the presence of soluble, fragmented DNA.

The results were as follows. Cells infected with d120 deletion mutant yielded high amounts of fragmented DNA which were readily visible on agarose gels stained with ethidium bromide. These ladders were not seen in agarose gels containing electrophoretically separated extracts of wild-type infected cells or E5 cells infected with d120. When Vero cells were incubated in medium containing phosphonoacetate, fragmented DNA was detected from cells infected with d120 mutant but not with the wild-type. Fragmented DNA was visible in extracts of mock-infected cells incubated at 39.5°C, but not in cells infected with HSV-1 tsHA1 and incubated at the same temperature.

From this series of studies, it is concluded that (i) HSV-1 is capable of inducing the morphologic and biochemical changes characteristic of apoptosis and these changes are prominent in cells infected with a mutant lacking ICP4; (ii) wild-type virus does not induce apoptosis indicating that ICP4 or a protein expressed subsequently is able to protect cells from apoptosis; (iii) the protective, anti-apoptotic effect is a viral function which does not depend on

the onset of viral DNA synthesis; (iv) DNA degradation typical of apoptosis was observed upon incubation at 39.5°C in mock-infected but not HSV-1_{ts}HA1 infected cells, which suggests that prolonged incubation at the elevated temperature can induce apoptosis that is blocked by a viral function expressed early.

5

EXAMPLE 3

ICP4 expresses an anti-apoptotic function.

In a fourth series of studies, Vero or E5 cells were mock infected or infected with 10 PFU per cell with either HSV-1(F) or d120. The cells were incubated at 39.5°C for 30 hrs. The rationale of these studies was as follows. As noted in Example 1, HSV-1(F) carries a ts lesion in the $\alpha 4$ gene and at the nonpermissive temperature (39.5°C) expresses only α genes. The $\alpha 4$ gene resident in the E5 cell line and the d120 mutant virus lacking the $\alpha 4$ gene were derived from the HSV-1(KOS) strain which does not exhibit the *ts* phenotype. In addition, the $\alpha 4$ gene resident in the E5 cell line is induced after infection and is not expressed in uninfected cells. In the first series of studies, the cells were harvested, lysed, centrifuged to sediment chromosomal DNA and the supernatant fluids were processed as described in Example 1 and subjected to electrophoresis in agarose gels.

The results were as follows. Fragmented DNA was present in lanes containing electrophoretically separated extracts of mock-infected Vero cells, Vero cells infected with d120 mutant, and the mock infected E5 cells. Fragmented DNA was not detected in Vero cells infected with wild-type virus, or in E5 cells infected with either d120 mutant virus or HSV-1(F) virus.

In the second series of studies Vero cells were mock infected, or infected with either d120 or with wild-type virus. After 30 hrs of incubation at 39.5°C, the cells were fixed and labeled with biotinylated dUTP by terminal transferase, and reacted with fluorescent avidin. Fluorescence was detected in mock-infected or infected with d120 mutant, but not in cells infected with wild-type virus.

These studies allowed permit the conclusion conclude that HSV-1(F) $\alpha 4$ gene encodes a function which blocks apoptosis reflected in the degradation of DNA, and that this function is

separable from the repressor and transactivator functions of ICP4 which are affected by the temperature sensitive lesion of the $\alpha 4$ gene of HSV-1(F).

A summary of the results is provided in Table 4. Induction of (+), or protection from (-) apoptosis is indicated upon conditions (infecting virus and incubation temperature) which induce
 5 apoptosis in Vero and E5 cell lines. "nt" indicates not tested.

TABLE 4

	VERO (37°C)	VERO (39°C)	E5 (37°C)	E5 (39.5°C)
MOCK	-	+	-	+
HSV-1(F)	-	-	-	-
HSV-1 d120	+	+	-	-
HSV-1 <u>ts</u> HA1	-	-	nt	-

10

EXAMPLE 4

HSV-1(KOS)d120 carries an additional mutation.

The results described in this section emerged from studies designed to repair the deletion in both copies of the $\alpha 4$ gene of HSV-1(KOS)d120. The inventors isolated recombinant in which this gene was repaired by two different procedures. In the first, the
 15 inventors cloned an HSV-1(F) DNA fragment that contains an $\alpha 4$ sequence plus enough flanking sequence to allow homologous recombination. In this series of studies Vero cells were transfected with plasmid DNA and infected with 0.1 to 1 PFU of HSV-1(KOS)d120 per cell. Under these conditions, plaques formed only in cultures of cells transfected with the plasmid DNA. Recombinant virus was recovered from individual plaques, and designated 120FR [for
 20 HSV-1(F) repair].

The second procedure was based on the observation that a small amount of virus recombines with the resident $\alpha 4$ gene in the E5 cell line to yield rescued virus capable of replicating efficiently in the absence of exogenous source of ICP4. The observed recombination frequency is 10^{-6} to 10^{-7} and therefore such rescued virus would be expected to
 25 be present in HSV-1(KOS)d120 stock. To isolate these recombinants, Vero cells were infected

at a high multiplicity with HSV-1 d120. At 24 hr after infection cells were harvested, frozen-thawed and serial dilutions were used to infect Vero cells. The recombinant virus obtained in this fashion was designated 120KR [for HSV-1(KOS) repair].

As shown in FIG. 3, analyses of DNA extracted from replicate Vero cell cultures infected with HSV-1(KOS)d120, 120FR or 120KR showed ladders typical of apoptotic cells. These ladders were absent in extracts of mock-infected cells or cells infected with HSV-1(F). The inventors conclude from these studies that HSV-1(KOS)d120 genome contain an additional mutation other than in the $\alpha 4$ gene.

EXAMPLE 5

**The U_S3 protein kinase is required to
block apoptosis induced by HSV-1 infection.**

In the following series of studies, the inventors defined the region that contains the additional mutation in HSV-1(KOS)d120 by rescue of the HSV-1(KOS)d120 with cosmids containing large HSV-1 DNA fragments. The three cosmids used in these studies were cosmid pBC8008, which contains all of the HSV-1 terminal repeat sequence, almost all of the U_S sequence, and part of the U_L sequence (FIG. 1) and cosmids pBC8004 and pBC8009 which contain fragments spanning over the entire repeat sequence but differ in the extent of coverage of the U_S region. Individual plaques purified from each transfection were tested for their ability to protect infected cells from apoptosis induced by infection. The results shown in Table 5 suggested that the second mutation in HSV-1(KOS)d120 may map in the U_S domain containing the genes U_S1 through U_S3.

TABLE 5

Plasmid/Cosmid	Recombinant	Protection From Apoptosis
pRB5166	HSV-1 120FR	0/9
none	HSV-1 120KR	0/5
pBC1004	HSV-1 120AR	1/4
pBC1009	HSV-1 120BR	0/9
pBC1008	HSV-1 120CR	8/9

To map the function required to block apoptosis more precisely, the inventors took
 5 advantage of the availability in this laboratory of several deletion mutants which span the
 sequence thought to encode the gene required to block apoptosis in infected cells. Recombinant
 virus R325 lacks the carboxyl terminal half of the $\alpha 22$ gene, and the 3' domain of the U_s2 gene.
 Recombinant virus R7041, lacks most of the U_s3 gene whereas in recombinant R7306 the U_s3
 gene had been repaired. The results, shown in FIG. 3 indicate that apoptosis was induced in
 10 cells infected with R7041 (ΔU_s3) but not in cells infected with the other mutants.

Two series of studies verified the conclusion that a functional U_s3 gene is required for
 prevention of apoptosis and that the second mutation in the HSV-1(KOS)d120 resides in the
 U_s3 gene. In the first series, the inventors carried out simple complementation tests to
 determine whether the second mutation in HSV-1(KOS)d120 was the same as that in the
 15 rescued virus or in R7041 (ΔU_s3) recombinant. Specifically Vero cells were infected with
 artificial mixtures of 120FR and HSV-1(KOS)d120, 120FR and R7041, or 120FR and R7306
 (U_s3 repaired). The results, shown in FIG. 4 indicate the following. As could be expected,
 120FR did not complement HSV-1(KOS)d120, the parent virus from which it was derived.
 The second, mixture of 120FR and R7041 also did not complement each other suggesting that
 20 120FR and its parent virus, HSV-1(KOS)d120 contained a nonfunctional U_s3 . Verification of
 this hypothesis emerged from the observation that R7306 containing a repaired U_s3 gene
 complemented 120FR and blocked apoptosis in cells infected with these two viruses.

The second series of studies served to verify the HSV-1(KOS)d120 and its derivatives
 lacked a functional U_s3 gene. As described in this introduction, the production of U_L34 gene

has been shown in earlier studies from this laboratory to be a substrate for the U_S3 protein kinase. In wild type infected cells, U_L34 has an apparent M_r of 30,000 whereas in cells infected with R7041 (ΔU_S3), U_L34 has an apparent migrates of M_r 33,000. Inasmuch as the original studies were done in BHK cells, in this series of studies replicate cultures of BHK cells were

5 infected 10 PFU of HSV-1(F), 120FR, R7041, and R7306 per cell. The results, shown in FIG. 5 indicate that the fully processed U_L34 protein was present in cells infected with HSV-1(F) but not cells infected with 120FR or R7041. As could be expected, the cells infected with HSV-1(KOS)d120 did not make detectable quantities of U_L34 protein inasmuch as they lack the $\alpha 4$ gene. In the absense of $\alpha 4$ gene expression there is no β or γ gene expression and therefore, no

10 U_S3 gene expression. Taken together, the inventors' results indicate the U_S3 kinase is functionally absent in HSV-1(KOS)d120 and 120FR. The inventors conclude that U_S3 is required for protection from apoptosis induced by HSV-1.

XI. References

The following references, to the extent that they provide exemplary procedural details or other information supplementary to that set forth herein, are incorporated by reference:

- 5 Baichwal and Sugden, *In: Gene Transfer*, Kucherlapati, R., ed. New York: Plenum Press, 117-148, 1986.
- Batterson and Roizman, *J. Virol.*, 46:371-377, 1983.
- Benvenisty and Neshif, *Proc. Natl. Acad. Sci. USA*, 83:9551-9555, 1986.
- Bittner *et al.*, *Methods in Enzymol.*, 153:516-544, 1987.
- 10 Brutlag *et al.*, *CABIOS*, 6:237-245, 1990.
- Campbell *et al.*, *J. Mol. Biol.*, 180:1-19, 1984.
- Chen and Okayama, *Mol. Cell Biol.*, 7:2745-2752, 1987.
- Chou and Fasman, *Adv. Enzymol. Relat. Areas Mol. Biol.* 47:45-148, 1978a.
- Chou and Fasman, *Ann. Rev. Biochem.* 47:251-276, 1978b.
- 15 Chou and Fasman, *Biochemistry*, 13(2):211-222, 1974b.
- Chou and Fasman, *Biochemistry*, 13(2):222-245, 1974a.
- Chou and Fasman, *Biophys. J.*, 26:367-384, 1979.
- Chou and Roizman, *Proc. Natl. Acad. Sci. USA*, 89:3266-3270, 1992.
- Clem and Miller, *In: Apoptosis II: The Molecular Basis of Apoptosis in Disease*, L. D. Tomei
20 and F. O. Cope, eds. (Cold Spring Harbor Laboratory Press), 89-110, 1994a.
- Conley *et al.*, *J. Virol.*, 37:191-206, 1981.
- DeLuca *et al.*, *J. Virol.*, 56:558-570, 1985.
- Dixon and Shaffer, *J. Virol.*, 36:189-203, 1980.
- Dubensky *et al.*, *Proc. Natl. Acad. Sci. USA*, 81:7529-7533, 1984.
- 25 Ejercito *et al.*, *J. Gen. Virol.*, 2:357-364, 1968.
- Faber and Wilcox, *Nucleic Acids Res.*, 14:6067-6083, 1986.
- Fechheimer *et al.*, *Proc. Natl. Acad. Sci. USA*, 84:8463-8467, 1987.
- Ferkol *et al.*, *FASEB J.*, 7:1081-1091, 1993.
- Fetrow and Bryant, *Biotechnology*, 11:479-483, 1993.
- 30 Fraley *et al.*, *Proc. Natl. Acad. Sci. USA*, 76:3348-3352, 1979.

- Freshner, "Animal Cell Culture: A Practical Approach," Second Edition, Oxford/New York, IRL Press, Oxford University Press, 1992.
- Ghosh and Bachhawat, Wu G. and C. Wu ed. In: *Liver diseases, targeted diagnosis and therapy using specific receptors and ligands*, New York: Marcel Dekker, 87-104, 1991.
- 5 Glorioso *et al.*, *Ann. Rev. Microbiol.* 49:675-710, 1995.
- Gopal, *Mol. Cell Biol.*, 5:1188-1190, 1985.
- Gorczyca *et al.*, *Cancer Res.*, 53:1945-1951, 1993.
- Graham and Van Der Eb, *Virology*, 52:456-467, 1973.
- Harland and Weintraub, *J. Cell Biol.*, 101:1094-1099, 1985.
- 10 Henderson *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:8479-8483, 1993.
- Herz and Roizman, *Cell*, 33:145-151, 1983.
- Holland *et al.*, *Virology*, 101:10-18, 1980.
- Honess and Roizman, *J. Virol.*, 14:8-19, 1974.
- Honess and Roizman, *J. Virol.*, 16:1308-1326, 1975.
- 15 Jameson and Wolf, *Comput. Appl. Biosci.*, 4(1):181-186, 1988.
- Johnson *et al.*, In: *Biotechnology and Pharmacy*, Pezzuto *et al.*, eds., Chapman and Hall, New York, 1993.
- Kaneda *et al.*, *Science*, 243:375-378, 1989.
- Kato *et al.*, *J. Biol. Chem.*, 266:3361-3364, 1991.
- 20 Klein *et al.*, *Nature*, 327:70-73, 1987.
- Koyama and Miwa, *J. Virol.*, 71 (3) p2567-71, 1997.
- Kristie and Roizman, *Proc. Natl. Acad. Sci. USA*, 83:3218-3222, 1986a.
- Kristie and Roizman, *Proc. Natl. Acad. Sci. USA*, 83:4700-4704, 1986b.
- Kuddus *et al.*, *J. Virol.*, 69:5568-5575, 1995.
- 25 Kyte and Doolittle, *J. Mol. Biol.*, 157(1):105-132, 1982.
- Leader, *et al.*, *Biochim. Biophys. Acta.*, 1091:426-431, 1991.
- Lemaster and Roizman, *J. Virol.*, 35:798-811, 1980.
- Leopardi *et al.*, *J. Virol.*, 69:3042-3048, 1995.
- Leopardi *et al.*, *J. Virol.*, 71(2):1133-9, 1997.
- 30 Leopardi and Roizman, *Proc. Natl. Acad. Sci. USA*, 93:9583-9587.
- Longnecker and Roizman, *Science*, 236:573-576, 1987.

- McCarthy *et al.*, *Proc. Natl. Acad. Sci. USA*, 91:3979-83, 1994.
- Michael and Roizman, *Proc. Natl. Acad. Sci. USA*, 86:9808-9812, 1989.
- Michael and Roizman, *Proc. Natl. Acad. Sci. USA*, 90:2286-2290, 1993.
- Michael *et al.*, *Science*, 239:1531-1534, 1988.
- 5 Meignier, *et al.*, *Virology*, 162:251-254, 1988.
- Mizrahi, *Process Biochem.*, (August):9-12, 1983.
- Muller, *J. Virol.*, 61:858-865, 1987.
- Nicolas and Rubenstein, In: *Vectors: A survey of molecular cloning vectors and their uses*, Rodriguez and Denhardt (eds.), Stoneham: Butterworth, 494-513, 1988.
- 10 Nicolau and Sene, *Biochem. Biophys. Acta*, 721:185-190, 1982.
- Nicolau *et al.*, *Methods Enzymol.*, 149:157-176, 1987.
- Pan and Griep, *Genes Dev.*, 8:1285-99, 1994.
- Perales *et al.*, *Proc. Natl. Acad. Sci. USA*, 91:4086-4090, 1994.
- Phillips *et al.*, In: *Large Scale Mammalian Cell Culture* (Feder, J. and Tolbert, W. R., eds.), Academic Press, Orlando, FL, U.S.A., 1985.
- 15 Post *et al.*, *Cell*, 24:555-565, 1981.
- Post and Roizman, *Cell*, 25:227-232, 1981.
- Potter *et al.*, *Proc. Natl. Acad. Sci. USA*, 81:7161-7165, 1984.
- Purves, *et al.*, *Biochim. Biophys. Acta.*, 889:208-215, 1986.
- 20 Purves, *et al.*, *J. Virol.*, 61:2896-2901, 1987.
- Purves, *et al.*, *J. Virol.*, 4295-4303, 1992.
- Purves, *et al.*, *J. Virol.*, 65:5757-5764, 1991.
- Rao *et al.*, *Proc. Natl. Acad. Sci. USA*, 89:7742-7746, 1992.
- Ray *et al.*, *Cell*, 69:597-604, 1992.
- 25 Ridgeway, Rodriguez, Denhardt, ed. In: *Vectors: A survey of molecular cloning vectors and their uses*, Stoneham: Butterworth, 467-492, 1988.
- Rippe *et al.*, *Mol. Cell Biol.*, 10:689-695, 1990.
- Roizman and Sears, In *Fields' Virology*, 3rd Edition, eds. Fields, *et al.* (Raven Press, New York, N.Y.), 2231-2295, 1996.
- 30 Sarre, *Byosistems*, 22:311-325, 1989.
- Shen and Shenk, *Curr. Opin. Genet. Dev.*, 5:105-111, 1995.

- Sheldrick and Bertholet, *Cold Spring Harbor Symp. Quant. Biol.*, 34:667-678, 1974.
- Shepard and DeLuca, *J. Virol.*, 65:787-795, 1991.
- Temin, In: *Gene Transfer*, Kucherlapati (ed.), New York: Plenum Press, 149-188, 1986.
- Tur-Kaspa *et al.*, *Mol. Cell Biol.*, 6:716-718, 1986.
- 5 Wadsworth, *et al.*, *J. Virol.*, 15:1487-1497, 1975.
- Wagner *et al.*, *Science*, 260:1510-1513, 1990.
- Weinberger *et al.*, *Science*, 228:740-742, 1985.
- White and Gooding, In: *The Molecular Basis of Apoptosis in Disease*, L. D. Tomei and F. O. Cope, eds. (Cold Spring Harbor Laboratory Press), 111-141, 1994.
- 10 White, *Genes and Dev.*, 7:2277-2284, 1993.
- Wolf *et al.*, *Comput. Appl. Biosci.*, 4(1):187-191, 1988.
- Wong *et al.*, *Gene*, 10:87-94, 1980.
- Wu and Wu, *Adv. Drug Delivery Rev.*, 12:159-167, 1993.
- Wu and Wu, *Biochemistry*, 27:887-892, 1988.
- 15 Wu and Wu, *J. Biol. Chem.*, 262:4429-4432, 1987.
- Wyllie *et al.*, *Int. Rev. Cytol.*, 68:251-306, 1980.
- Yang *et al.*, *Proc. Natl. Acad. Sci. USA*, 87:9568-9572, 1990.
- Zelenin *et al.*, *FEBS Lett.*, 280:94-96, 1991.
- Zhu *et al.*, *J. Virol.*, 69:7960-7970, 1995.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: Arch Development Corporation
(B) STREET: 1101 East 58th Street
(C) CITY: Chicago
(D) STATE: IL
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 60637
(G) TELEPHONE: 512-418-3000
(H) TELEFAX: 512-474-7577

(ii) TITLE OF INVENTION: HERPES SIMPLEX VIRUS U_s3 AND ICP4 AS
INHIBITORS OF APOPTOSIS

(iii) NUMBER OF SEQUENCES: 6:

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: US 08/843,659

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4257 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GCTGCTCCTC CTTCCCGCCG GCCCCTGGGA CTATATGAGC CCGAGGACGC CCCGATCGTC	60
CACACGGAGC GCGGCTGCCG ACACGGATCC ACGACCCGAC GCGGGACCGC CAGAGACAGA	120
CCGTCAGACG CTCGCCGCGC CGGGACGCCG ATACGCGGAC GAAGCGCGGG AGGGGGATCG	180
GCCGTCCTTG TCCTTTTTTC CACCCAAGCA TCGACCGGTC CGCGCTAGTT CCGCGTCGAC	240
GGCGGGGGTC GTCGGGGTCC GTGGGTCTCG CCCCCTCCCC CCATCGAGAG TCCGTAGGTG	300
ACCTACCGTG CTACGTCCGC CGTCGCAGCC GTATCCCCGG AGGATCGCCC CGCATCGGCG	360
ATGGCGTCGG AGAACAAGCA GCGCCCCGGC TCCCCGGGCC CCACCGACGG GCCGCCGCC	420
ACCCGAGCC CAGACCGCGA CGAGCGGGGG GCCCTCGGGT GGGGCGCGGA GACGGAGGAG	480

GGCGGGGACG	ACCCCGACCA	CGACCCCGAC	CACCCCCACG	ACCTCGACGA	CGCCCGGCGG	540
GACGGGAGGG	CCCCCGCGGC	GGGCACCGAC	GCCGGCGAGG	ACGCCGGGGA	CGCCGTCTCG	600
CCGCGACAGC	TGGCTCTGCT	GGCCTCCATG	GTAGAGGAGG	CCGTCCGGAC	GATCCCGACG	660
CCCGACCCCG	CGGCCTCGCC	GCCCCGGACC	CCCGCCTTTC	GAGCCGACGA	CGATGACGGG	720
GACGAGTACG	ACGACGCAGC	CGACGCCGCC	GGCGACCGGG	CCCCGGCCCC	GGGCCGCGAA	780
CGGGAGGCCC	CGCTACGCGG	CGCGTATCCG	GACCCACAGG	ACCGCCTGTC	GCCGCGCCCC	840
CCGGCCCAGC	CGCCCGGGAG	ACGTCGTCAC	GGCCGGTGCC	GGCCATCGGC	GTCATCGACC	900
TCGTCCGACT	CCGGGTCCCTC	GTCCTCGTCG	TCCGCATCCT	CTTCGTCCCTC	GTCGTCCGAC	960
GAGGACGAGG	ACGACGACGG	CAACGACGCG	GCCGACCACG	CACGCGAGGC	GCGGGCCGTC	1020
GGGCGGGGTC	CGTCGAGCGC	GGCGCCGGCA	GCCCCCGGGC	GGACGCCGCC	CCCGCCCGGG	1080
CCACCCCCCC	TCTCCGAGGC	CGCGCCCAAG	CCCCGGGCGG	CGGCGAGGAC	CCCCGCGGCC	1140
TCCGCGGGCC	GCATCGAGCG	CCGCCGGGCC	CGCGCGGCGG	TGGCCGGCCG	CGACGCCACG	1200
GGCCGCTTCA	CGGCCGGGCA	GCCCCGGCGG	GTCGAGCTGG	ACGCCGACGC	GACCTCCGGC	1260
GCCTTCTACG	CGCGCTATCG	CGACGGGTAC	GTCAGCGGGG	AGCCGTGGCC	CGGCGCCGGG	1320
CCCCCGCCCC	CGGGGCGGGT	GCTGTACGGC	GGCCTGGGCG	ACAGCCGCCC	GGGCCTCTGG	1380
GGGGCGCCCC	AGGCGGAGGA	GGCGCGACGC	CGGTTGAGG	CCTCGGGCGC	CCCGGCGGCC	1440
GTGTGGGCGC	CCGAGCTGGG	CGACGCCGCG	CAGCAGTACG	CCCTGATCAC	GCGGCTGCTG	1500
TACACCCCGG	ACGCGGAGGC	CATGGGGTGG	CTCCAGAACC	CGCGCGTGTT	CCCCGGGGAC	1560
GTGGCGCTGG	ACCAGGCCTG	CTTCCGGATC	TCGGGCGCCG	CGCGCAACAG	CAGCTCCTTC	1620
ATCACCGGCA	GCGTGGCGCG	GGCCGTGCCC	CACCTGGGCT	ACGCCATGGC	GGCCGGCCGC	1680
TTCCGCTGGG	GCCTGGCGCA	CGCGGCGGCC	GCCGTGGCCA	TGAGCCGCCG	ATACGACCGC	1740
GCGCAGAAGG	GCTTCCTGCT	GACCAGCCTG	CGCCGCGCCT	ACGCGCCCCT	GTTGGCGCGC	1800
GAGAACGCGG	CGCTGACGGG	GGCCGCGGGG	AGCCCCGGCG	CCGGCGCAGA	TGACGAGGGG	1860
GTCGCCGCCG	TCGCCGCCGC	CGCACCGGGC	GAGCGCGCGG	TGCCCCCGCG	GTACGGCGCC	1920
GCGGGGATCC	TCGCCGCCCT	GGGGCGGCTG	TCCGCCGCGC	CCGCCTCCCC	CGCGGGGGGC	1980
GACGACCCCG	ACGCCGCCCG	CCACGCCGAC	GCCGACGACG	ACGCCGGGCG	CCGCGCCCAG	2040
GCCGGCCGCG	TGGCCGTCGA	GTGCCTGGCC	GCCTGCCGCG	GGATCCTGGA	GGCGCTGGCC	2100
GAGGGCTTCG	ACGGCGACCT	GGCGGCCGTC	CCGGGGCTGG	CCGGGGCCCC	GCCCGCCAGC	2160

CCCCCGCGGC	CGGAGGGACC	CGCGGGCCCC	GCTTCCCCGC	CGCCGCCGCA	CGCCGACGCG	2220
CCCCGCCTGC	GCGCGTGGCT	GCGCGAGCTG	CGGTTCGTGC	GCGACGCGCT	GGTGCTCATG	2280
CGCCTGCGCG	GGGACCTGCG	CGTGGCCGGC	GGCAGCGAGG	CCGCCGTGGC	CGCCGTGCGC	2340
GCCGTGAGCC	TGGTCGCCGG	GGCCCTGGGC	CCC GCGCTGC	CGCGGGACCC	GCGCCTGCCG	2400
AGCTCCGCGG	CCGCCGCCGC	CGCGGACCTG	CTGTTTGACA	ACCAGAGCCT	GCGCCCCCTG	2460
CTGGCGGCGG	CGGCCAGCGC	ACCGGACGCC	GCCGACGCGC	TGGCGGCCGC	CGCCGCCTCC	2520
GCCGCGCCGC	GGGAGGGGCG	CAAGCGCAAG	AGTCCCGGCC	CGGCCCGGCC	GCCCGGAGGC	2580
GGCGGCCCCG	GACCCCCGAA	GACGAAGAAG	AGCGGCGCGG	ACGCCCCCGG	CTCGGACGCC	2640
CGCGCCCCCC	TCCCCGCGCC	CGCGCCCCCC	TCCACGCCCC	CGGGGCCCCG	GCCCGCCCCC	2700
GCCCAGCCCC	CGGCGCCCCG	GGCCGCCGCG	GCGCAGGCCC	GCCCGCGCCC	CGTGGCCGTG	2760
TCGCGCCGGC	CCGCCGAGGG	CCCCGACCCC	CTGGGCGGCT	GGCGGCGGCA	GCCCCCGGGG	2820
CCCAGCCACA	CGGCGGCGCC	CGCGGCCGCC	GCCCTGGAGG	CCTACTGCTC	CCCGCGCGCC	2880
GTGGCCGAGC	TCACGGACCA	CCCCTGTTC	CCCCTCCCCT	GGCGACCGGC	CCTCATGTTT	2940
GACCCGCGGG	CCCTGGCCTC	GATCGCCGCG	CGGTGCGCCG	GGCCCGCCCC	CGCCGCCCAG	3000
GCCGCGTGCG	GCGGCGGCGA	CGACGACGAT	AACCCCCACC	CCCACGGGGC	CGCCGGGGGC	3060
CGCCTCTTTG	GCCCCCTGCG	CGCCTCGGGC	CCGCTGCGCC	GCATGGCGGC	CTGGATGCGC	3120
CAGATCCCCG	ACCCCGAGGA	CGTGCGCGTG	GTGGTGCTGT	ACTCGCCGCT	GCCGGGCGAG	3180
GACCTGGCCG	GCGGCGGGGC	CTCGGGGGGG	CCGCCGGAGT	GGTCCGCCGA	GCGCGGCGGG	3240
CTGTCCTGCC	TGCTGGCGGC	CCTGGCCAAC	CGGCTGTGCG	GGCCGGACAC	GGCCGCCTGG	3300
GCGGGCAATT	GGACCGGCGC	CCCCGACGTG	TCGGCGCTGG	GCGCACAGGG	CGTGCTGCTG	3360
CTGTCCACGC	GGGACCTGGC	CTTCGCCGGG	GCCGTGGAGT	TTCTGGGGCT	GCTCGCCAGC	3420
GCCGGCGACC	GGCGGCTCAT	CGTGGTCAAC	ACCGTGCGCG	CCTGCGACTG	GCCCGCCGAC	3480
GGGCCCGCGG	TGTCGCGGCA	GCACGCCTAC	CTGGCGTGCG	AGCTGCTGCC	CGCCGTGCAG	3540
TGCGCCGTGC	GCTGGCCGGC	GGCGCGGGAC	CTGCGCCGCA	CGGTGCTGGC	CTCGGGCCGC	3600
GTGTTGCGCC	CGGGGGTCTT	CGCGCGCGTG	GAGGCCGCGC	ACGCGCGCCT	GTACCCCGAC	3660
GCGCCGCCGC	TGCGCCTGTG	CCGCGGCGGC	AACGTGCGCT	ACCGCGTGCG	CACGCGCTTC	3720
GGCCCGGACA	CGCCGGTGCC	CATGTCCCCG	CGCGAGTACC	GCCGGGCCGT	GCTGCCGGCG	3780
CTGACGCGCC	GGGCGGCGGC	CTCGGGGACC	ACCGACGCCA	TGGCGCCCGG	GCGCGCGGAC	3840


```

TTCTGCGAGG AGGAGGCCCA CTCGCACGCC GCCTGCGCGC GCTGGGGCCT GGGCGCGCCG      3900
CTGCGGCCCCG TGTACGTGGC GCTGGGGCGC GAGGCGGTGC GCGCCGGCCC GGCCCGGTGG      3960
CGCGGGCCCGC GGAGGGACTT TTGCGCCCGC GCCCTGCTGG AGCCCGACGA CGACGCCCCC      4020
CCGCTGGTGC TGC CGGCGCA CGACGACGGC CCGGGGGCCC TGCCGCCGGC GCCGCCGGG      4080
ATTCTGCTGGG CCTCGGCCAC GGGCCGCAGC GGCACCGTGC TGGCGGCGGC GGGGGCCGTG      4140
GAGGTGCTGG GGGCGGAGGC GGGCTTGCC ACGCCCCCGC GGCGGGAAGT TGTGGACTGG      4200
GAAGGCGCCT GGGACGAAGA CGACGCGGC GCGTTCGAGG GGGACGGGGT GCTGTAA      4257

```

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1298 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```

Met Ala Ser Glu Asn Lys Gln Arg Pro Gly Ser Pro Gly Pro Thr Asp
1           5           10           15

Gly Pro Pro Pro Thr Pro Ser Pro Asp Arg Asp Glu Arg Gly Ala Leu
20          25          30

Gly Trp Gly Ala Glu Thr Glu Glu Gly Gly Asp Asp Pro Asp His Asp
35          40          45

Pro Asp His Pro His Asp Leu Asp Asp Ala Arg Arg Asp Gly Arg Ala
50          55          60

Pro Ala Ala Gly Thr Asp Ala Gly Glu Asp Ala Gly Asp Ala Val Ser
65          70          75          80

Pro Arg Gln Leu Ala Leu Leu Ala Ser Met Val Glu Glu Ala Val Arg
85          90          95

Thr Ile Pro Thr Pro Asp Pro Ala Ala Ser Pro Pro Arg Thr Pro Ala
100         105         110

Phe Arg Ala Asp Asp Asp Asp Gly Asp Glu Tyr Asp Asp Ala Ala Asp
115         120         125

Ala Ala Gly Asp Arg Ala Pro Ala Arg Gly Arg Glu Arg Glu Ala Pro
130         135         140

Leu Arg Gly Ala Tyr Pro Asp Pro Thr Asp Arg Leu Ser Pro Arg Pro
145         150         155         160

```

64

Pro Ala Gln Pro Pro Arg Arg Arg Arg His Gly Arg Trp Arg Pro Ser
 165 170 175
 Ala Ser Ser Thr Ser Ser Asp Ser Gly Ser Ser Ser Ser Ser Ser Ala
 180 185 190
 Ser Ser Ser Ser Ser Ser Ser Asp Glu Asp Glu Asp Asp Asp Gly Asn
 195 200 205
 Asp Ala Ala Asp His Ala Arg Glu Ala Arg Ala Val Gly Arg Gly Pro
 210 215 220
 Ser Ser Ala Ala Pro Ala Ala Pro Gly Arg Thr Pro Pro Pro Pro Gly
 225 230 235 240
 Pro Pro Pro Leu Ser Glu Ala Ala Pro Lys Pro Arg Ala Ala Ala Arg
 245 250 255
 Thr Pro Ala Ala Ser Ala Gly Arg Ile Glu Arg Arg Arg Ala Arg Ala
 260 265 270
 Ala Val Ala Gly Arg Asp Ala Thr Gly Arg Phe Thr Ala Gly Gln Pro
 275 280 285
 Arg Arg Val Glu Leu Asp Ala Asp Ala Thr Ser Gly Ala Phe Tyr Ala
 290 295 300
 Arg Tyr Arg Asp Gly Tyr Val Ser Gly Glu Pro Trp Pro Gly Ala Gly
 305 310 315 320
 Pro Pro Pro Pro Gly Arg Val Leu Tyr Gly Gly Leu Gly Asp Ser Arg
 325 330 335
 Pro Gly Leu Trp Gly Ala Pro Glu Ala Glu Glu Ala Arg Arg Arg Phe
 340 345 350
 Glu Ala Ser Gly Ala Pro Ala Ala Val Trp Ala Pro Glu Leu Gly Asp
 355 360 365
 Ala Ala Gln Gln Tyr Ala Leu Ile Thr Arg Leu Leu Tyr Thr Pro Asp
 370 375 380
 Ala Glu Ala Met Gly Trp Leu Gln Asn Pro Arg Val Val Pro Gly Asp
 385 390 395 400
 Val Ala Leu Asp Gln Ala Cys Phe Arg Ile Ser Gly Ala Ala Arg Asn
 405 410 415
 Ser Ser Ser Phe Ile Thr Gly Ser Val Ala Arg Ala Val Pro His Leu
 420 425 430
 Gly Tyr Ala Met Ala Ala Gly Arg Phe Gly Trp Gly Leu Ala His Ala
 435 440 445
 Ala Ala Ala Val Ala Met Ser Arg Arg Tyr Asp Arg Ala Gln Lys Gly
 450 455 460

Phe Leu Leu Thr Ser Leu Arg Arg Ala Tyr Ala Pro Leu Leu Ala Arg
 465 470 475 480
 Glu Asn Ala Ala Leu Thr Gly Ala Ala Gly Ser Pro Gly Ala Gly Ala
 485 490 495
 Asp Asp Glu Gly Val Ala Ala Val Ala Ala Ala Ala Pro Gly Glu Arg
 500 505 510
 Ala Val Pro Ala Gly Tyr Gly Ala Ala Gly Ile Leu Ala Ala Leu Gly
 515 520 525
 Arg Leu Ser Ala Ala Pro Ala Ser Pro Ala Gly Gly Asp Asp Pro Asp
 530 535 540
 Ala Ala Arg His Ala Asp Ala Asp Asp Ala Gly Arg Arg Ala Gln
 545 550 555 560
 Ala Gly Arg Val Ala Val Glu Cys Leu Ala Ala Cys Arg Gly Ile Leu
 565 570 575
 Glu Ala Leu Ala Glu Gly Phe Asp Gly Asp Leu Ala Ala Val Pro Gly
 580 585 590
 Leu Ala Gly Ala Arg Pro Ala Ser Pro Pro Arg Pro Glu Gly Pro Ala
 595 600 605
 Gly Pro Ala Ser Pro Pro Pro His Ala Asp Ala Pro Arg Leu Arg
 610 615 620
 Ala Trp Leu Arg Glu Leu Arg Phe Val Arg Asp Ala Leu Val Leu Met
 625 630 635 640
 Arg Leu Arg Gly Asp Leu Arg Val Ala Gly Gly Ser Glu Ala Ala Val
 645 650 655
 Ala Ala Val Arg Ala Val Ser Leu Val Ala Gly Ala Leu Gly Pro Ala
 660 665 670
 Leu Pro Arg Asp Pro Arg Leu Pro Ser Ser Ala Ala Ala Ala Ala Ala
 675 680 685
 Asp Leu Leu Phe Asp Asn Gln Ser Leu Arg Pro Leu Leu Ala Ala Ala
 690 695 700
 Ala Ser Ala Pro Asp Ala Ala Asp Ala Leu Ala Ala Ala Ala Ala Ser
 705 710 715 720
 Ala Ala Pro Arg Glu Gly Arg Lys Arg Lys Ser Pro Gly Pro Ala Arg
 725 730 735
 Pro Pro Gly Gly Gly Gly Pro Arg Pro Pro Lys Thr Lys Lys Ser Gly
 740 745 750

Ala Asp Ala Pro Gly Ser Asp Ala Arg Ala Pro Leu Pro Ala Pro Ala
 755 760 765
 Pro Pro Ser Thr Pro Pro Gly Pro Glu Pro Ala Pro Ala Gln Pro Ala
 770 775 780
 Ala Pro Arg Ala Ala Ala Ala Gln Ala Arg Pro Arg Pro Val Ala Val
 785 790 795 800
 Ser Arg Arg Pro Ala Glu Gly Pro Asp Pro Leu Gly Gly Trp Arg Arg
 805 810 815
 Gln Pro Pro Gly Pro Ser His Thr Ala Ala Pro Ala Ala Ala Leu
 820 825 830
 Glu Ala Tyr Cys Ser Pro Arg Ala Val Ala Glu Leu Thr Asp His Pro
 835 840 845
 Leu Phe Pro Val Pro Trp Arg Pro Ala Leu Met Phe Asp Pro Arg Ala
 850 855 860
 Leu Ala Ser Ile Ala Ala Arg Cys Ala Gly Pro Ala Pro Ala Ala Gln
 865 870 875 880
 Ala Ala Cys Gly Gly Gly Asp Asp Asp Asn Pro His Pro His Gly
 885 890 895
 Ala Ala Gly Gly Arg Leu Phe Gly Pro Leu Arg Ala Ser Gly Pro Leu
 900 905 910
 Arg Arg Met Ala Ala Trp Met Arg Gln Ile Pro Asp Pro Glu Asp Val
 915 920 925
 Arg Val Val Val Leu Tyr Ser Pro Leu Pro Gly Glu Asp Leu Ala Gly
 930 935 940
 Gly Gly Ala Ser Gly Gly Pro Pro Glu Trp Ser Ala Glu Arg Gly Gly
 945 950 955 960
 Leu Ser Cys Leu Leu Ala Ala Leu Ala Asn Arg Leu Cys Gly Pro Asp
 965 970 975
 Thr Ala Ala Trp Ala Gly Asn Trp Thr Gly Ala Pro Asp Val Ser Ala
 980 985 990
 Leu Gly Ala Gln Gly Val Leu Leu Leu Ser Thr Arg Asp Leu Ala Phe
 995 1000 1005
 Ala Gly Ala Val Glu Phe Leu Gly Leu Leu Ala Ser Ala Gly Asp Arg
 1010 1015 1020
 Arg Leu Ile Val Val Asn Thr Val Arg Ala Cys Asp Trp Pro Ala Asp
 1025 1030 1035 1040
 Gly Pro Ala Val Ser Arg Gln His Ala Tyr Leu Ala Cys Glu Leu Leu
 1045 1050 1055

Pro Ala Val Gln Cys Ala Val Arg Trp Pro Ala Ala Arg Asp Leu Arg
 1060 1065 1070
 Arg Thr Val Leu Ala Ser Gly Arg Val Phe Gly Pro Gly Val Phe Ala
 1075 1080 1085
 Arg Val Glu Ala Ala His Ala Arg Leu Tyr Pro Asp Ala Pro Pro Leu
 1090 1095 1100
 Arg Leu Cys Arg Gly Gly Asn Val Arg Tyr Arg Val Arg Thr Arg Phe
 1105 1110 1115 1120
 Gly Pro Asp Thr Pro Val Pro Met Ser Pro Arg Glu Tyr Arg Arg Ala
 1125 1130 1135
 Val Leu Pro Ala Leu Asp Gly Arg Ala Ala Ala Ser Gly Thr Thr Asp
 1140 1145 1150
 Ala Met Ala Pro Gly Ala Pro Asp Phe Cys Glu Glu Glu Ala His Ser
 1155 1160 1165
 His Ala Ala Cys Ala Arg Trp Gly Leu Gly Ala Pro Leu Arg Pro Val
 1170 1175 1180
 Tyr Val Ala Leu Gly Arg Glu Ala Val Arg Ala Gly Pro Ala Arg Trp
 1185 1190 1195 1200
 Arg Gly Pro Arg Arg Asp Phe Cys Ala Arg Ala Leu Leu Glu Pro Asp
 1205 1210 1215
 Asp Asp Ala Pro Pro Leu Val Leu Arg Gly Asp Asp Asp Gly Pro Gly
 1220 1225 1230
 Ala Leu Pro Pro Ala Pro Pro Gly Ile Arg Trp Ala Ser Ala Thr Gly
 1235 1240 1245
 Arg Ser Gly Thr Val Leu Ala Ala Ala Gly Ala Val Glu Val Leu Gly
 1250 1255 1260
 Ala Glu Ala Gly Leu Ala Thr Pro Pro Arg Arg Glu Val Val Asp Trp
 1265 1270 1275 1280
 Glu Gly Ala Trp Asp Glu Asp Asp Gly Gly Ala Phe Glu Gly Asp Gly
 1285 1290 1295
 Val Leu

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1446 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

```

ATGGCCTGTC GTAAGTTTTC TCGCGTTTAC GGGGGACAGG GCAGGAGGAA GGAGGAGGCC      60
GTCCCGCCCG AGACAAAGCC GTCCCGGGTG TTTCCTCATG GCCCCTTTTA TACCCAGCC      120
GAGGACGCGT GCCTGGACTC CCCGCCCCCG GAGACCCCA AACCTTCCA CACCACACCA      180
CCCAGCGAGG CCGAGCGCCT GTGTCATCTG CAGGAGATCC TTGCCAGAT GTACGGAAC      240
CAGGACTACC CCATAGAGGA CGACCCAGC GCGGATGCCG CGGACGATGT CGACGAGGAC      300
GCCCCGGAGC ACGTGGCCTA TCCGGAGGAA TACGCAGAGG AGCTTTTCT GCCCCGGGAC      360
GCGACCGGTC CCCTTATCGG GGCCAACGAC CACATCCCTC CCCCCTGTGG CGCATCTCCC      420
CCCGGTATAC GACGACGAG CCGGGATGAG ATTGGGGCCA CGGGATTAC CGCGGAAGAG      480
CTGGACGCCA TGGACAGGGA GGCGGCTCGA GCCATCAGCC GCGGCGGCAA GCCCCCTCG      540
ACCATGGCCA AGCTGGTGAC TGGCATGGGC TTTACGATCC ACGGAGCGCT CACCCAGGA      600
TCGGAGGGGT GTGTCTTTGA CAGCAGCCAT CCAGATTACC CCCAACGGGT AATCGTGAAG      660
GCGGGGTGGT ACACGAGCAC GAGCCACGAG GCGCGACTGC TGAGGCGACT GGACCACCCG      720
GCGATCCTGC CCCTCCTGGA CCTGCATGTC GTCTCCGGG TCACGTGTCT GGTCTCCCC      780
AAGTACCAGG CCGACCTGTA TACCTATCTG AGTAGGCGCC TGAACCACT GGGACGCCCC      840
CAGATCGCAG CGGTCTCCCG GCAGCTCCTA AGCGCCGTTG ACTACATTCA CCGCCAGGGC      900
ATTATCCACC GCGACATTAA GACCGAAAAT ATTTTATTA ACACCCCGA GGACATTTGC      960
CTGGGGGACT TTGGCGCCGC GTGCTTCGTG CAGGGTTCCC GATCAAGCCC CTCCCCTAC     1020
GGAATCGCCG GAACCATCGA CACCAACGCC CCCGAGGTCC TGGCCGGGGA TCCGTATACC     1080
ACGACCGTCG ACATTGGAG CGCCGTCTG GTGATCTTCG AGACTGCCGT CCACAACGCG     1140
TCCTTGTCT CGGCCCCCG CGGCCCCAAA AGGGGCCCGT GCGACAGTCA GATCACCCGC     1200
ATCATCCGAC AGGCCAGGT CCACGTTGAC GAGTTTCCC CGCATCCAGA ATCGCGCTC     1260
ACCTCGCGCT ACCGCTCCCG CGCGCCGGG AACAAATCGCC CGCCGTACAC CCGACGGCC     1320
TGGACCGCT ACTACAAGAT GGACATAGAC GTCGAATATC TGGTTTGCAA AGCCCTCACC     1380

```

TTCGACGGCG CGCTTCGCCC CAGCGCCGCA GAGCTGCTTT GTTGGCCGCT GTTCAACAG 1440
 AAATGA 1446

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 481 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met	Ala	Cys	Arg	Lys	Phe	Cys	Arg	Val	Tyr	Gly	Gly	Gln	Gly	Arg	Arg	1	5	10	15
Lys	Glu	Glu	Ala	Val	Pro	Pro	Glu	Thr	Lys	Pro	Ser	Arg	Val	Phe	Pro	20	25	30	
His	Gly	Pro	Phe	Tyr	Thr	Pro	Ala	Glu	Asp	Ala	Cys	Leu	Asp	Ser	Pro	35	40	45	
Pro	Pro	Glu	Thr	Pro	Lys	Pro	Ser	His	Thr	Thr	Pro	Pro	Ser	Glu	Ala	50	55	60	
Glu	Arg	Leu	Cys	His	Leu	Gln	Glu	Ile	Leu	Ala	Gln	Met	Tyr	Gly	Asn	65	70	75	80
Gln	Asp	Tyr	Pro	Ile	Glu	Asp	Asp	Pro	Ser	Ala	Asp	Ala	Ala	Asp	Asp	85	90	95	
Val	Asp	Glu	Asp	Ala	Pro	Asp	Asp	Val	Ala	Tyr	Pro	Glu	Glu	Tyr	Ala	100	105	110	
Glu	Glu	Leu	Phe	Leu	Pro	Gly	Asp	Ala	Thr	Gly	Pro	Leu	Ile	Gly	Ala	115	120	125	
Asn	Asp	His	Ile	Pro	Pro	Pro	Cys	Gly	Ala	Ser	Pro	Pro	Gly	Ile	Arg	130	135	140	
Arg	Arg	Ser	Arg	Asp	Glu	Ile	Gly	Ala	Thr	Gly	Phe	Thr	Ala	Glu	Glu	145	150	155	160
Leu	Asp	Ala	Met	Asp	Arg	Glu	Ala	Ala	Arg	Ala	Ile	Ser	Arg	Gly	Gly	165	170	175	
Lys	Pro	Pro	Ser	Thr	Met	Ala	Lys	Leu	Val	Thr	Gly	Met	Gly	Phe	Thr	180	185	190	
Ile	His	Gly	Ala	Leu	Thr	Pro	Gly	Ser	Glu	Gly	Cys	Val	Phe	Asp	Ser	195	200	205	
Ser	His	Pro	Asp	Tyr	Pro	Gln	Arg	Val	Ile	Val	Lys	Ala	Gly	Trp	Tyr	210	215	220	

Thr Ser Thr Ser His Glu Ala Arg Leu Leu Arg Arg Leu Asp His Pro
 225 230 235 240
 Ala Ile Leu Pro Leu Leu Asp Leu His Val Val Ser Gly Val Thr Cys
 245 250 255
 Leu Val Leu Pro Lys Tyr Gln Ala Asp Leu Tyr Thr Tyr Leu Ser Arg
 260 265 270
 Arg Leu Asn Pro Leu Gly Arg Pro Gln Ile Ala Ala Val Ser Arg Gln
 275 280 285
 Leu Leu Ser Ala Val Asp Tyr Ile His Arg Gln Gly Ile Ile His Arg
 290 295 300
 Asp Ile Lys Thr Glu Asn Ile Phe Ile Asn Thr Pro Glu Asp Ile Cys
 305 310 315 320
 Leu Gly Asp Phe Gly Ala Ala Cys Phe Val Gln Gly Ser Arg Ser Ser
 325 330 335
 Pro Phe Pro Tyr Gly Ile Ala Gly Thr Ile Asp Thr Asn Ala Pro Glu
 340 345 350
 Val Leu Ala Gly Asp Pro Tyr Thr Thr Thr Val Asp Ile Trp Ser Ala
 355 360 365
 Gly Leu Val Ile Phe Glu Thr Ala Val His Asn Ala Ser Leu Phe Ser
 370 375 380
 Ala Pro Arg Gly Pro Lys Arg Gly Pro Cys Asp Ser Gln Ile Thr Arg
 385 390 395 400
 Ile Ile Arg Gln Ala Gln Val His Val Asp Glu Phe Ser Pro His Pro
 405 410 415
 Glu Ser Arg Leu Thr Ser Arg Tyr Arg Ser Arg Ala Ala Gly Asn Asn
 420 425 430
 Arg Pro Pro Tyr Thr Arg Pro Ala Trp Thr Arg Tyr Tyr Lys Met Asp
 435 440 445
 Ile Asp Val Glu Tyr Leu Val Cys Lys Ala Leu Thr Phe Asp Gly Ala
 450 455 460
 Leu Arg Pro Ser Ala Ala Glu Leu Leu Cys Leu Pro Leu Phe Gln Gln
 465 470 475 480
 Lys

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Arg Arg Arg Arg Thr Arg Arg Ser Arg Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:4
- (D) OTHER INFORMATION:/note= "Residue may be arginine or
any amino acid residue."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:5
- (D) OTHER INFORMATION:/note= "Residue may be either
serine or threonine."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:6
- (D) OTHER INFORMATION:/note= "Residue may be either
arginine or tyrosine."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Arg Arg Arg Arg Ser Arg
1 5

CLAIMS

1. A method for blocking apoptosis of a cell comprising the step of providing to said cell an HSV U_S3 polypeptide.
- 5 2. The method of claim 1, wherein said providing comprises contacting said cell with said HSV U_S3 polypeptide.
3. The method of claim 1, wherein said providing comprises contacting said cell with an HSV U_S3 gene.
- 10 4. The method of claim 3, wherein said gene is contained in an expression vector.
5. The method of claim 4, wherein said gene is under the transcriptional control of a promoter active in eukaryotic cells.
- 15 6. The method of claim 5, wherein said promoter is a tetracycline controlled promoter.
7. The method of claim 6, wherein said expression vector further comprises a selectable marker.
- 20 8. The method of claim 7, wherein said expression vector further comprises a gene encoding a second polypeptide under the transcriptional control of a promoter active in eukaryotic cells.
- 25 9. The method of claim 8, wherein said second gene encodes an HSV ICP4 polypeptide.
10. A method for inducing apoptosis in a cell infected with HSV comprising the step of administering to said cell an agent that inhibits HSV U_S3 function in said cell.
- 30 11. The method of claim 10, wherein said agent inhibits transcription of an HSV U_S3 gene.

12. The method of claim 10, wherein said agent inhibits translation of an HSV U_S3 gene transcript.
- 5 13. The method of claim 10, wherein said agent binds to an HSV U_S3 polypeptide.
14. The method of claim 11, wherein said reagent is an antisense HSV U_S3 construct.
15. The method of claim 12, wherein said reagent is an antisense HSV U_S3 construct.
- 10 16. The method of claim 13, wherein said reagent is an antibody that binds immunologically to an HSV U_S3 polypeptide.
17. The method of claim 14, wherein said construct comprises an oligonucleotide that
15 hybridizes to a 5'-untranslated region for an HSV U_S3 gene.
18. The method of claim 15, wherein said construct comprises an oligonucleotide that hybridizes to a translational start site for an HSV U_S3 transcript.
- 20 19. The method of claim 16, wherein said antibody is a monoclonal antibody.
20. The method of claim 9, further comprising the step of administering to said cell an agent that inhibits HSV ICP4 function in said cell.
- 25 21. The method of claim 20, wherein said agent inhibits translation of an HSV ICP4 gene transcript.
22. The method of claim 20, wherein said agent binds to an HSV ICP4 polypeptide.
- 30 23. The method of claim 20, wherein said agent inhibits transcription of an HSV α 4 gene.

24. The method of claim 21, wherein said reagent is an antisense HSV ICP4 construct.
25. The method of claim 23, wherein said reagent is an antisense HSV ICP4 construct.
- 5 26. The method of claim 22, wherein said reagent is an antibody that binds immunologically to an HSV ICP4 polypeptide.
27. The method of claim 24, wherein said construct comprises an oligonucleotide that hybridizes to a 5'-untranslated region for an HSV α 4 gene.
- 10 28. The method of claim 23, wherein said construct comprises an oligonucleotide that hybridizes a translational start site for an HSV ICP4 transcript.
29. The method of claim 26, wherein said antibody is a monoclonal antibody.
- 15 30. A method for treating a subject with an HSV infection comprising the step of inhibiting HSV U_S3 function.
31. The method of claim 30, wherein the inhibition comprises providing to said subject a first pharmaceutical composition comprising an HSV U_S3 antisense construct.
- 20 32. The method of claim 30, wherein the inhibition comprises providing to said subject a first pharmaceutical composition comprising a monoclonal antibody that binds immunologically to an HSV U_S3 polypeptide.
- 25 33. The method of claim 31, wherein said first pharmaceutical composition is applied topically to HSV infected cells in said patient..
34. The method of claim 32, wherein said first pharmaceutical composition is applied topically to HSV infected cells in said patient.
- 30

35. The method of claim 30, further comprising the step of inhibiting HSV ICP4 function.
36. The method of claim 30, further comprising the step of providing to said subject a second pharmaceutical composition comprising a conventional anti-HSV agent.
- 5 37. The method of claim 36, wherein said second pharmaceutical composition comprises acyclovir.
- 10 38. The method of claim 37, wherein said acyclovir is delivered via a route selected from the group consisting of topically, orally and intravenously.
39. A screening method for compounds having inhibitory activity against HSV U_S3 polypeptide-induced inhibition of apoptosis comprising the steps of:
- 15 (a) providing a first cell comprising an HSV U_S3 gene under the control of an HSV immediate early promoter;
- (b) infecting said first cell with a herpes simplex virus that lacks a functional U_S3 gene;
- (c) contacting said first cell with a test compound;
- (d) incubating said first cell under conditions permitting viral replication; and
- 20 (e) comparing the cell pathology of said first cell following incubation with (i) the cell pathology of a second cell that lacks an HSV U_S3 gene following infection with said herpes simplex virus and (ii) the cell pathology of a third cell comprising an HSV U_S3 gene under the control of an HSV immediate early promoter following infection with said herpes simplex virus but in the absence of
- 25 said test compound.
40. The method of claim 39, wherein said cell pathology comprises condensation of chromatin, obliteration of nuclear membranes, vacuolization, cytoplasmic blebbing and DNA fragmentation.

41. The method of claim 39, wherein said cell line contains an integrated copy of a wild-type HSV U_S3 gene under the control of an U_S3 promoter.

5 42. The method of claim 41, wherein said herpes simplex virus that lacks a functional HSV U_S3 gene has a deletion in both copies of the virally-encoded U_S3 genes.

43. The method of claim 42, wherein said herpes virus that lacks a functional HSV U_S3 gene carries a temperature sensitive mutation in both copies of the virally-encoded U_S3 gene and the incubation is at 39.5°C.
10

44. A screening method for compounds having inhibitory activity against HSV U_S3-induced inhibition of apoptosis comprising the steps of:

- 15 (a) providing a first cell comprising an HSV U_S3 gene under the control of an inducible promoter;
- (b) inducing transcription from said promoter;
- (c) contacting said first cell with a test compound;
- (d) incubating said first cell under conditions permitting expression of an HSV U_S3 polypeptide; and
- 20 (e) comparing the cell pathology of said first cell following incubation with (i) the cell pathology of a second cell not having an HSV U_S3 gene following induction and (ii) the cell pathology of a third cell comprising an HSV U_S3 gene under the control of an inducible promoter following induction but in the absence of said test compound.

25

45. A screening method for compounds having inhibitory activity against HSV U_S3 polypeptide-induced inhibition of apoptosis comprising the steps of:

- (a) providing a first cell;
- (b) infecting said first cell with a herpes simplex virus;

- (c) contacting said first cell with a test compound;
- (d) incubating said first cell under conditions permitting viral replication; and
- (e) comparing the cell pathology of said first cell following incubation with (i) the cell pathology of a second cell treated with said test compound alone and (ii) the cell pathology of a third cell following infection with said herpes simplex virus but in the absence of said test compound.

5 46. A method for expressing a polypeptide in a cell comprising the steps:

- (a) contacting a cell with a herpes virus vector encoding said polypeptide;
- 10 (b) contacting said cell with an agent that blocks the transactivating function of U_S3 but does not block the apoptosis inhibiting function of U_S3.

47. A method for the identification of a candidate substance that is a modulator of US3-kinase activity comprising the steps of:

- 15 (a) providing an enzyme composition comprising U_S3 protein kinase and a threonine/serine protein substrate;
- (b) contacting said composition with said candidate substance under conditions that allow phosphorylation;
- (c) determining the phosphorylation of said threonine/serine substrate; and
- 20 (d) comparing the phosphorylation of said threonine/serine substrate with the phosphorylation of said threonine/serine substrate in the absence of a candidate inhibitor substance;

wherein an increase in phosphorylation is indicative of said candidate substance being a stimulator of phosphorylation and a decrease in phosphorylation of said threonine/serine substrate is indicative of said candidate being an inhibitor of phosphorylation.

25 48. An inhibitor of U_S3-kinase activity identified according to a method comprising the steps of:

(a) providing an enzyme composition comprising U₅3 protein kinase and a threonine/serine protein substrate;

(b) contacting said composition with said candidate substance under conditions that allow phosphorylation;

5 (c) determining the phosphorylation of said threonine/serine substrate; and

(d) comparing the phosphorylation of said threonine/serine substrate with the phosphorylation of said threonine/serine substrate in the absence of a candidate inhibitor substance;

10 wherein a decrease in phosphorylation of said threonine/serine substrate is indicative of said candidate being an inhibitor of phosphorylation.

49. A stimulator of U₅3-kinase activity identified according to a method comprising the steps of:

15 (a) providing an enzyme composition comprising U₅3 protein kinase and a threonine/serine protein substrate;

(b) contacting said composition with said candidate substance under conditions that allow phosphorylation;

(c) determining the phosphorylation of said threonine/serine substrate; and

20 (d) comparing the phosphorylation of said threonine/serine substrate with the phosphorylation of said threonine/serine substrate in the absence of a candidate inhibitor substance;

wherein an increase in phosphorylation is indicative of said candidate substance being a stimulator of phosphorylation.

1/5





FIG. 1


2/5



BEST AVAILABLE COPY

FIG. 2

3/5



BEST AVAILABLE COPY

FIG. 3

4/5




FIG. 4

BEST AVAILABLE COPY

5/5




FIG. 5

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N 15/86, C07K 14/035, C12N 15/11, C07K 16/18, G01N 33/50, A61K 48/00, 35/76</p>	<p>A3</p>	<p>(11) International Publication Number: WO 98/46637 (43) International Publication Date: 22 October 1998 (22.10.98)</p>
<p>(21) International Application Number: PCT/US98/07573 (22) International Filing Date: 16 April 1998 (16.04.98) (30) Priority Data: 08/843,659 16 April 1997 (16.04.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/843,659 (CON) Filed on 16 April 1997 (16.04.97) (71) Applicant (for all designated States except US): ARCH DEVELOPMENT CORPORATION [US/US]; 1011 East 58th Street, Chicago, IL 60637 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LEOPARDI, Rosario [IT/US]; 5107 S. Blackstone (906), Chicago, IL 60615 (US). ROIZMAN, Bernard [US/US]; 5555 S. Everett Avenue, Chicago, IL 60637 (US). (74) Agent: HIGHLANDER, Steven, L.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 28 January 1999 (28.01.99)</p>	

(54) Title: HERPES SIMPLEX VIRUS U_S3 AND ICP4 AS INHIBITORS OF APOPTOSIS

(57) Abstract

The ICP4 protein of herpes simplex virus plays an important role in the transactivation of viral genes. The present invention discloses that ICP4 also has the ability to inhibit apoptosis. This function appears to reside in functional domain distinct from the transactivating function, as indicated by studies using temperature sensitive mutants of ICP4 that have transactivating function at elevated temperatures. Also disclosed are methods for inhibition of apoptosis using ICP4 or an ICP4 encoding gene, such as an α 4 gene, methods for inhibiting ICP4's apoptosis-inhibiting function, and methods for the production of recombinant proteins and treatment of HSV infections. Further, the present invention discloses that the HSV-1 mutant lacking the α 4 gene, has a secondary mutation in the gene U_S3 specifying a protein kinase. Thus a functional U_S3, a viral gene encoding a protein kinase known to phosphorylate serine/threonine within a specific arginine rich consensus sequence, is required in order to block apoptosis. Also disclosed are methods for inhibition of apoptosis using U_S3 or an U_S3 encoding gene, methods for inhibiting U_S3's apoptosis-inhibiting function, and methods for the production of recombinant proteins and treatment of HSV infections.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 98/07573

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/86 C07K14/035 C12N15/11 C07K16/18 G01N33/50 A61K48/00 A61K35/76		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	R. LEOPARDI ET AL: "The herpes simplex virus major regulatory protein IPC4 blocks apoptosis induced by the virus by hipertermia" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES , vol. 93, no. 18, September 1996, pages 9583-9587, XP002049963 Washington, DC, US see the whole document --- -/-	1,9, 20-29
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 28 October 1998		Date of mailing of the international search report 11/11/1998
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo rd, Fax: (+31-70) 340-3016		Authorized officer Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/07573

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	A.H. KOYAMA AND Y. MIWA: "Supression of apoptotic DNA fragmentation in herpes simplex virus type 1-infected cells" JOURNAL OF VIROLOGY, vol. 71, no. 3, 1997, pages 2567-2571, XP002082373 READING, GB cited in the application see the whole document ---	1,39-49
A	WO 97 10349 A (ARCH DEV CORP) 20 March 1997 see the whole document ---	1-49
A	WO 96 00007 A (UNIV GEORGETOWN) 4 January 1996 see the whole document ---	1-49
P,X	R. LEOPARDI ET AL., : "The herpes simplex virus 1 protein kinase Us3 is required for protection from apoptosis induced by the virus" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 94, no. 15, 22 July 1997, pages 7891-7896, XP000197988 WASHINGTON DC, US see the whole document ---	1-9
P,X	V. GALVAN AND B. ROIZMAN: "Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 95, no. 7, 31 March 1998, pages 3931-3936, XP002079995 WASHINGTON DC, US see the whole document ---	1-9, 39-49
P,X	WO 98 04709 A (ARCH DEV CORP) 5 February 1998 see the whole document -----	1,9, 20-38

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/07573

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 30-38
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 30-38
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.: 48, 49
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
Claims 48, 49 refer to agonists and antagonists substances which are not
sufficiently disclosed in the application (lack of technical disclosure).
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/07573

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9710349 A	20-03-1997	AU 6964596 A	01-04-1997
WO 9600007 A	04-01-1996	US 5585096 A	17-12-1996
		AU 679644 B	03-07-1997
		AU 2906095 A	19-01-1996
		AU 3988897 A	08-01-1998
		CA 2193491 A	04-01-1996
		EP 0766512 A	09-04-1997
		JP 10501990 T	24-02-1998
		US 5728379 A	17-03-1998
WO 9804709 A	05-02-1998	AU 3810597 A	20-02-1998